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ABSTRACT OF DISSERTATION

EFFECT OF AZITHROMYCIN ON MACROPHAGE PHENOTYPE DURING
PULMONARY INFECTIONS AND CYSTIC FIBROSIS

Azithromycin improves clinical outcomes in patients with cystic fibrosis
(CF), specifically in patients infected with Pseudomonas aeruginosa.
Azithromycin shifts macrophage programming away from a pro-inflammatory
classical (M1) phenotype, and towards an anti-inflammatory alternative (M2)
phenotype; however, little is known about this mechanism, nor of its impact upon
immune response to pulmonary infection. We set out to determine the
mechanism by which azithromycin is able to alter macrophage phenotype, and
assess the effect of azithromycin induced macrophage polarization on
inflammation during pulmonary infections.
Utilizing macrophage cell culture, we found that azithromycin increased
IKKβ, a signaling molecule in the NFκB pathway, which likely is altering
macrophage programming. Using a Pseudomonas infection model in mice that
lack physiologic alternative macrophage activation, we showed that
azithromycin’s ability to alter macrophage function and decrease lung damage
was independent of interleukin control of macrophage programming.
Azithromycin increased fibrotic protein production both in vivo and in vitro, but
blunted immune-driven fibrotic damage. We extended our study to patients with
CF, describing gene expression in macrophages isolated from sputum samples.
We found markers consistent with a shift toward M2 polarization in these
patients. These data suggest potential mechanisms by which azithromycin
benefits patients with CF.
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Chapter 1: Introduction
A. Overview
Cystic Fibrosis (CF) is a genetic disorder characterized by a deficiency in
the cystic fibrosis transmembrane regulator (CFTR) gene [11]. This deficiency
results in impaired chloride transfer in epithelial cells. This impairment results in
thickened secretions in the digestive and reproductive tracts, as well as in the
lungs. While impairments in the digestive and reproductive tracts can commonly
lead malnutrition and sterility, it is the pulmonary complications in patients that
lead to long term complications and mortality, with the average life expectancy of
patients with CF currently at 37 years [11]. Defects in the CFTR cause the lungs
of these patients to be characterized by increased mucus formation, providing a
breeding ground for a wide variety of bacteria to colonize, most notably the gram
negative bacterium Pseudomonas aeruginosa. The progression of the disease is
characterized by repeated acute bacterial flares, followed by a latent phase
where the bacteria are held in check by the immune system. The inflammatory
response in the lungs to these recurring infections contributes greatly to a decline
in lung function in these patients over time [11].
During acute bacterial flares, the lungs of these patients are characterized
by an influx of phagocytic and inflammatory cells, most notably neutrophils and
macrophages [12]. These inflammatory cells produce a wide variety of proinflammatory cytokines in the lungs. Additionally, the production of molecules
involved in the oxidative burst (e.g. nitric oxide) are up-regulated, resulting in
destruction of bacteria [13]. Unfortunately, these oxidative molecules also cause
considerable damage to the lungs of these patients. This inflammatory response
is necessary, as without it bacteria would over-proliferate. If the response is
overly zealous, however, a large amount of damage can occur in the lungs of
these patients. This results in airway remodeling, scarring, and a decline in lung
function over time in these patients. In the course of an individual infection of
bacterial flare, macrophages initially play an important role in phagocytosis and
inflammation; over time, however, they shift to an anti-inflammatory and pro1

fibrotic role. These cells play an important role in killing invading bacteria in the
lungs, and are responsible for the initiation of the inflammatory response to a
bacterial flare, [12]. These infections are treated with a wide variety of
medications, including oral, IV, and inhaled antibiotics [14]. In an attempt to
control the number of bacterial exacerbations, these patients also are commonly
treated with anti-inflammatory medications, including traditional agents (e.g.
corticosteroids and non-steroidal anti-inflammatory drugs). Ibuprofen has
traditionally been shown in patients with CF to prevent decline in FEV1 %
predicted, as well as improving survival. The medication is not routinely used in
patients with CF, however, due to the side effect profile associated with the
medication [15]. Additionally, azithromycin (AZM), an antibiotic that is utilized for
its anti-inflammatory properties.
AZM is a macrolide antibiotic that is commonly used in this patient
population. It has been shown in several clinical studies that chronic AZM
therapy improves clinical parameters in patients with CF, including forced
expiratory volume in one second (FEV1), incidence of acute bacterial flares, and
patient quality of life [16-20]. Unfortunately, long term usage of AZM as an antiinflammatory can contribute to increased bacterial resistance as well as to other
forms of collateral damage resistance [17]. An increased understanding of how
AZM alters immune responses and thereby improves clinical parameters in these
patients may lead to potential new therapeutics that provide the beneficial effects
of AZM without the need to for long-term antimicrobial use. Including much of
the work in this dissertation, our group has shown that AZM alters the function
and phenotype of macrophages in these patients, and hypothesize that this may
be one of the methods by which patients benefit from taking the drug.
B. Cystic fibrosis
Cystic fibrosis is an autosomal recessive disorder that results in a nonfunctional CFTR channel. The CFTR is a chloride channel found in multiple
organ systems, most notably the lung. The lung manifestations of CF are the
most impactful to patients over the course of their lifetime, contributing the most
2

to morbidity and mortality. While literally hundreds of mutations in the CFTR
have been observed, they can be grouped into 5 major groups. Class 1
mutations result in a shortened mRNA, and no CFTR protein production. Class 2
mutations result in misfolded mRNA, which is then degraded in the endoplasmic,
resulting in no CFTR protein production. The ΔF508 mutation, which represents
70% of all mutations in patients with CF, is a class 2 mutation [11]. In class 3
mutations, an inactive CFTR is produced. Class 4 mutations result in a CFTR
with decreased function. Finally, Class 5 mutations result in normal function, but
decreased expression of the CFTR [11, 21]. Interestingly, while different classes
of mutations can be correlated to disease severity for most organs affected with
CF (e.g. the gut, pancreas, and reproductive tracts), with classes 4 and 5
mutations being associated with less serious disease, this correlation does not
appear to exist in the lungs of patients with CF [22, 23].
In the lungs, a deficient CFTR leads to salt imbalances at the epithelial
surfaces, which then results in thickened and dehydrated secretions [11]. Not
only do these thickened secretions provide a breeding ground for a wide variety
of pathogens, but this also alters immune cell function in the lungs, making it
considerably more difficult for phagocytic cells to internalize and destroy bacteria
[11]. Acute flares of CF also involve an extensive neutrophilic response. During
an acute exacerbation of the disease, cytokines produced by macrophages,
including IL8, IL1 and TNF-α result in the recruitment of neutrophils to the lung.
Once they reach the lungs, they release elastases, and lyse, they release large
amounts of DNA into the lung as well [24]. These secreted factors and released
DNA provide the basis of the thickened secretions and impaired clearance of
organisms that plague the lungs of patients with CF [11]. The prolonged
inflammatory response that this causes also plays an important role in the
decline of lung function in patients with CF. Disease progression is characterized
by blockage of the small and medium bronchioles, although the alveoli are by
and large spared [11]. Additionally, there is evidence that the CFTR plays an
important role in the ability of phagocytic cells to acidify the phagosome. This
results in macrophages and monocytes in CF patients being less able to destroy
3

bacteria that they have internalized [25]. This is likely an additional reason why
patients with CF are unable to effectively clear the bacteriawith which they have
been colonized.
Patients with CF are colonized with a wide variety of pathogens, and once
colonized it is exceptionally difficult to clear these pathogens. The pattern of
bacterial colonization in patients with CF has shifted over time. Traditionally, P.
aeruginosa, methicillin-susceptible Staphlococcus aureus, and Haemophilus
influenzae have been the primary pathogens that patients that CF are colonized
with [26]. More recently, however, other bacteria are becoming increasingly
common in patients with CF, most notably methicillin-resistant Staphlococcus
aureus, although there has also been a great increase in patients colonized with
Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and various
mycobacteria [11, 26].
By far, however, P. aeruginosa is the most significant pathogen in patients
with CF [11]. The rate of colonization in patients with CF can exceed 70% in
adults, and even in young children the rate of colonization can exceed 25% [27,
28]. This pathogen produces thick alginate biofilms that aid its ability to survive
in this setting [29]. By hiding in biofilms, the bacteria is able to avoid
phagocytosis by macrophages and neutrophils, as well as avoid antibiotics.
Biofilms also may prevent complement from being able to bind to the organism’s
surface, preventing the bacteria from being targeted for destruction [30]. Indeed,
conversion from a non-biofilm producing strain to a biofilm producing strain is
considered one of the necessary steps for P. aeruginosa to permanently colonize
the lungs of patients, as opposed to being present in the lungs intermittently [30].
P. aeruginosa additionally produces elastases and proteases that allow it to
cleave host defense proteins, such as defensins, allowing it to remain in the
lungs of these patients [13]. P. aeruginosa is able to respond quickly to changes
in the host environment, allowing it to out-compete other bacteria [13]. The
biofilms that are formed also impair the ability of these patients to breathe, and
result in a decline in lung function for these patients over time. Evidence also
4

exists that P. aeruginosa is able to mutate more readily in patients with CF,
allowing it to gain resistance to the antibiotics used to treat these patients [31].
Hartl et. al. have shown that the lungs of patients with CF colonized with
P. aeruginosa showed increased concentrations of IL4 and IL13, and decreased
concentrations of IFNγ, consistent with a shift towards a Th2 polarization in the
lungs of these patients [32]. This difference was even more pronounced when
they assessed mRNA expression via qRT-PCR [32]. They also found that
patients colonized with P. aeruginosa displayed higher levels of the inflammatory
cytokine interleukin (IL)6 in their bronchoalveolar lavage fluid. In their P.
aeruginosa positive patients they additionally found a strong negative correlation
between IL4 and IL13 concentrations and FEV1 % predicted [32]. This further
suggests the negative repercussions associated with a shift to towards the Th2
phenotype in the lungs of these patients, and shows a method by which this shift
occurs. Contrariwise, this may represent a reactionary response to a decline in
lung function, with the increase in Th2 polarization being the response, rather
than the cause of decreased lung function. This shift may be attempting to
minimize further damage in the lungs of patients.
Patients with CF are treated with a wide variety of medications to manage
their pulmonary symptoms. Nebulized tobramycin is approved for use in patients
who have been colonized with P. aeruginosa [14]. Treatment with Dornase alfa,
a recombinant DNase, is common as well to help degrade the thickened
secretions that are common in patients with CF [14]. Patients receive a variety of
other antibiotics to control bacterial infections, and to attempt to decrease the
incidence of acute bacterial flares. Treatment with bronchodilators, as well as
chest percussion is also commonly used and has been shown to improve lung
function in these patients. It is also common for patients to receive dietary
enzymes to aid in digestion, and to take proton pump inhibitors to deal with other
symptoms associated with their disease [33]. While the wide variety of
treatments used in these patients greatly improves life span and patient quality of
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life, it makes clinical studies difficult due to confounding the data analysis in our
studies and the studies of others.
C. Macrophage Polarization
Macrophages are important effector cells in the innate immune system
[34]. Derived from circulating peripheral blood mononuclear cells (PBMCs), in
their traditional roles, they reside in organs, and function both as a sentinel to
invading bacteria, as well as one of the key phagocytic cells in the body. This
response is characterized by phagocytosis of pathogens, and production of
reactive oxygen species (ROS) [35]. Additionally, they secrete cytokines that
recruit other inflammatory cells to the site of an acute infection, primarily
neutrophils [36]. This robust inflammatory response, while necessary to destroy
the invading pathogen, is not without cost. The production of pro-inflammatory
cytokines, as well as ROS can lead to considerable tissue damage [37].
More recently, an additional phenotype for macrophage has been
elucidated. Alternatively activated macrophages (M2), as opposed to the
classically activated macrophages (M1) described above, play a very different
role in host defense to infections. M2 macrophages are primarily involved in
repairing the damage that is caused by a acute inflammatory injury. Their key
effector molecules are arginase, as well as polyamines, which are the precursors
to the extracellular (ECM) proteins fibronectin and collagen [38]. The production
of these fibrotic molecules is a necessary part of the repair process. These
molecules help damaged tissue regain integrity, and allow recovery from
inflammatory damage. Overproduction, however, can lead to scarring, fibrosis,
and organ damage. Indeed, in a variety of fibrotic lung diseases, it has been
shown that the alternatively activated macrophage is the predominate phenotype
in patients with these disorders [39]. Similar observations have been made for a
number of autoimmune disorders as well, most notably multiple sclerosis and
rheumatoid arthritis [38].

6

M1 and M2 macrophages are derived from inactive resident
macrophages, as well as circulating monocytes. They are polarized to the
classically or alternatively activated phenotype via signaling primarily from either
Th-1 or Th-2 polarized T-cells, respectively [9, 35]. Cells are polarized to the
classically activated phenotype via interferon-gamma (IFN-γ), in addition to
signaling from the toll like receptors (TLRs) including TLR4 triggered by
lipopolysaccharide (LPS). Macrophages can be polarized to the alternatively
activated phenotype via signaling from both IL4 and IL13 [3]. The two
prototypical effector proteins produced in the two phenotypes, iNOS and
arginase 1, appear to be reciprocally regulated, sharing the common substrate Larginine (Figure 1.1) [9, 10]. iNOS converts arginine to nitric oxide (NO) and
citrulline. NO is a key component in the oxidative burst, leading to destruction of
intracellular bacteria. It also, however, results in tissue damage, leading to
inflammation at the site of infection. Conversely, with alternative macrophage
polarization, the enzyme arginase is expressed and converts arginine to both
urea and ornithine. Ornithine is then converted to polyamines, which can then be
converted to precursors of matrix molecules including collagen. These proteins
form the building blocks for tissue repair that is necessary to recover from an
inflammatory response to bacteria, and if the damage is severe enough, results
in irreversible fibrotic changes [40-42]. It is important to note that, unlike T cells,
macrophage polarization occurs on a spectrum, and is not a terminal
differentiation. A cell polarized to the classically activated phenotype can later be
polarized to the alternatively activated phenotype, and vice versa [35].
The terminology used to describe macrophage polarization is a topic of
ongoing discussion. It is generally accepted that the classically activated
phenotype is relatively homogenous in its polarization and function. However,
alternatively activated macrophages are considerably more variable in their
description in terms of gene expression. An overview of the different phenotypes
of macrophages can be seen in Table 1.1. Mantovani et. al. describe 3 different
types of alternatively activated macrophages. M2a are polarized by IL4 and
IL13. These cells display high expression of surface mannose receptor, and
7

express proteins including IL10, IL1ra, and the decoy IL1RII. They describe
these macrophages as being heavily involved in type 2 inflammation, allergy, and
the killing and encapsulation of parasites. They describe M2b macrophages as
being activated by immune complexes and TLR or IL1R. M2b macrophages
express high levels of CD86, IL10, TNF, IL1 and IL6. These macrophages are
also known as type II macrophages, and are involved in immunoregulation and
Th2 activation. Finally, they describe an M2c phenotype. These macrophages
are activated by IL10, and express high levels of IL10, TGF-β, MR, and produce
pro-fibrotic proteins involved in matrix deposition [3]. Others group one or more
of these phenotypes together [1, 35]. In fact, rather than view macrophage
polarization as a spectrum with M1 or M2 macrophages on either pole of the
spectrum, some view there to be three primary poles of macrophage polarization,
with classically activated macrophages, wound healing macrophages (essentially
M2 macrophages), and regulatory macrophages representing the three poles,
and various tissue macrophages that display markers of the three different
phenotypes [35]. For the purposes of this dissertation, however, I will be treating
macrophage polarization as a duality. I will be describing macrophages as either
M1 or M2, although the M2 macrophages that I will be focusing on most closely
resemble the M2a phenotype that Mantovani et. al. described. This does not,
however, eliminate the possibility that AZM polarizes macrophages to a novel
phenotype, as opposed to polarizing to the traditionally thought of alternatively
activated phenotype. AZM may be polarizing macrophages to a novel phenotype
that avoids both the inflammatory component of an M1 macrophage and the profibrotic component of the M2 macrophage.
In the lung of the patient with CF during an acute bacterial infection, or
during an acute flare of a chronic infection, both resident and infiltrating
macrophages are quickly polarized by the cytokines in the lung milieu to the M1
phenotype. Additionally, M1 macrophages produce cytokines, including IL8, that
result in a strong neutrophilic response [11, 43]. The strong M1 polarization in
the lungs during an acute infection results in phagocytosis and destruction of
bacteria in the lung. This results in the up-regulation of inflammatory markers, as
8

well as free radical levels in the lung [44]. There is also evidence that
macrophages with deficient CFTR may indeed be playing a disproportionate role
in this strong inflammatory shiftby producing higher amounts of proinflammatory
cytokines including IL6 and TNFα as compared to macrophages with normal
CFTR function [45].
T cells play an important role in the orchestration of the immune response.
CD4+ T cells can be classified as having a T helper (Th) type 1, or a type 2
response. A Th1 response is characterized by production of the cytokine IFNγ,
and leads to activation of macrophages to efficiently kill phagocytosed
organisms, and a robust pro-inflammatory response [46]. A Th2 response, on
the other hand, is primarily characterized by IL4 production, and leads to
activation of humoral immunity. In addition, activation of the Th2 response leads
to production of cytokines that polarize macrophages towards the alternatively
activated phenotype in response to some pathogens [46]. In the lungs of
patients with CF, the Th1 polarization is traditionally associated with improved
outcomes. However, over time, a net shift to a Th2 polarization is observed in
these patients. This shift is associated with a worsening in outcomes in patients
with CF [47]. Indeed in other fibrotic lung diseases, most notably idiopathic
pulmonary fibrosis, a vicious cycle persists in the lungs, wherein the Th2
polarization shifts macrophages to the alternatively activated phenotype, leading
to increased production of collagen in the lungs of these patients, and a decline
in lung function [48]. Others have shown that targeting IL4 and IL13-responsive
cells (including macrophages and fibroblasts) in fibrotic lung disease in animals
can lead to decreased fibrosis [49]. While similar findings have not yet been
observed in patients with CF, it is reasonable to surmise that the damage caused
during acute flares of CF results in an inordinately strong shift to the M2
phenotype, causing scarring and fibrosis in the lungs of these patients. While T
cells coordinate the adaptive and chronic phases of host defense, macrophages
also coordinate aspects of chronic inflammation in the lungs and in other tissues
[50, 51]. Instead of the inflammatory response maturing into a more T celldominated process, in CF the response continues to be neutrophil-driven,
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described by other investigators as more of a “sustained acute response” in
contrast to a maturing, chronic inflammation [52]. While in normal circumstances
this repair and remodeling is both necessary and beneficial in patients, in the
face of the dysregulated inflammatory response in CF and the excessive damage
that then results, it leads to pulmonary functional decline.
This exaggerated immune response, while necessary to respond to the
acute infection, is not without costs. Considerable debris is accumulated in the
lungs in the aftermath of an infection. This debris consists of portions of bacteria,
as well as dead and dying epithelial cells and macrophages [53]. Alternatively
activated macrophages are able to efficiently internalize and destroy this cellular
debris [35]. They also produce profibrotic proteins, providing the necessary
building materials for tissue repair to occur [54]. This repair commonly results in
scarring and fibrosis of the lungs, especially when the initial immune response is
robust [55]. Unfortunately, this scarring can lead to decreases in the parameters
of lung function, including FEV1 % predicted [11]. This decline additionally
increases the probability of a future acute bacterial flare, and the cycle of a
damaging inflammatory response followed by tissue repair and remodeling is
responsible for much of the mortality associated with CF [15]. The remodeling
occurs primarily in the peribronchiolar regions of the lungs, with considerable
bronchiectasis and scarring occurring in the lungs of these patients over time.
Damage to the alveoli of the lungs is much less common, and also less severe in
patients with CF, although it does occur in some patients, especially those with
severe disease [56].
D. Azithromycin
AZM is a macrolide antibiotic that is commonly used for a variety of
infections. It functions as a bacteriostatic agent and has clinically effective
activity against both gram positive and negative organisms [57]. It binds to the
50s subunit of bacterial ribosomes and inhibits bacterial protein synthesis by
blocking elongation of the peptide chain [58]. Interestingly, the drug is
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extensively concentrated in immune cells:concentrations in alveolar
macrophages have been reported to be 170 fold higher than in serum [58].
AZM is one of the drugs of choice for a wide variety of infections. The
drug has been shown to be effective in a large percentage of community
acquired pneumonia cases caused by the typical pathogens associated with this
infection, including Streptococcus pneumoniae, and atypical organisms such as
Chlamydia pneumoniae, Legionella sp., and Mycoplasma pneumoniae. [58]. Its
spectrum of activity combined with the ease of administration results in it
commonly being used for acute exacerbations of chronic bronchitis, otitis media
infections, streptococcal pharyngitis, sinusitis, and both upper and lower
respiratory tract infections [58].
Additionally, it has been shown that the macrolides exert antiinflammatory effects independent of their effects on microorganisms [59].
Patients with advanced CF derive their benefits from the anti-inflammatory, rather
than the anti-infective properties of the medication. Indeed, it appears to be a
class effect of the macrolides, with clarithromycin displaying a less potent effect
on inflammation, while roxithromycin (not approved for clinical use in the United
States) is more potent [59]. Macrolides have also been shown to decrease
inflammatory cytokine concentrations in the lungs, including IL6, IL8, and TNFα
[37, 60]. It has been shown that while AZM does not destroy P. aeruginosa, it
does exert indirect effects on the bacteria. AZM decreases transcription of the
quorum sensing genes lasR and rhlR, resulting in a decrease in the production of
bacterial virulence factors [61]. Importantly, it has been shown that treatment
with macrolides decreases neutrophil influx in the lungs of patients with CF [62].
The importance of this effect, as well as the determination of a molecular
mechanism by which this effect occurs is currently unknown.
Key to the development of this project, our lab has demonstrated that AZM
is able to shift macrophage polarization away from the classically activated
phenotype, and towards the alternatively activated phenotype, even in the
presence of M1 stimulating cytokines [63]. We showed that macrophages
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treated with AZM, bacterial LPS, and IFNγ increased expression of macrophage
surface markers that was consistent with macrophages treated with IL4/IL13 and
LPS. We also published that AZM treated macrophages exhibit increased
arginase activity, as well as decreased expression of the iNOS protein. Finally,
we showed that the pattern of cytokine expression in macrophages treated with
AZM is less inflammatory, and more anti-inflammatory than macrophages that
did not receive AZM [63].
AZM has been shown in a variety of studies to be beneficial for patients
with CF. It has been shown to improve lung function, measured via the FEV1%
predicted [16, 18]. Saimin et. al. have found this is a mild increase, on the order
of 3-4% over the placebo group over the course of 3-6 months. Subjects with CF
were randomized to receive either AZM or a placebo. Interestingly, this
difference disappeared once the patients were taken off the medication [18].
This group went on to separately analyze data from both patients colonized with
P. aeruginosa, as well as patients who have not been colonized with the
organism. While differences in FEV1% predicted occur in both patients in both
groups, the effect is much more pronounced in subjects who have been
colonized with P. aeruginosa [17, 18]. Additionally, they found that CF patients
treated with AZM are more likely to go longer without an acute lung exacerbation
of their disease, a result that was consistent over 2 trials performed by this group
[18, 19]. Additionally, AZM increases the time to a first exacerbation in both
patients colonized with P. aeruginosa, as well as patients who have not been
colonized with P. aeruginosa [17, 18].
Equi et. al. utilized a cross-over design with both AZM and a placebo, and
found that the treatment group had a slight but significant increase in FEV1 %
predicted on the order of 10% [16]. They also found that differences in FEV1%
predicted declined when patients were taken off of the medication. Subjects who
were receiving AZM were additionally less likely to be taking other oral antibiotics
to control their symptoms, although they did not find significant differences in
hospitalization rates between the two groups [16].
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Finally, Wolter et. al., in addition to finding similar results as the other
groups with regard to lung function, also found that AZM treated patients were
significantly less likely to receive IV antibiotics. They also investigated C-reactive
protein levels, a marker of systemic inflammation in the blood of these patients.
They found that patients treated with AZM showed decreased C-reactive protein
levels in their blood at the end of 3 months of treatment with AZM, as compared
to patients that received a placebo. Finally they had patients complete quality of
life questionnaires both before and after treatment. Patients reported less
dyspnea and fatigue, as well as general improvements in their quality of life [20].
As one might expect, long term treatment with AZM is not without
repercussions in these patients. In patients with CF treated with AZM, there
were significant increases in the amount of bacteria resistant to macrolides in
one of the trials outlined above [17]. Specifically, the rates of macrolide resistant
S. aureus increased from 28% to 37% over 6 months, while the rates of
macrolide resistant H. influenzae increased from 1% to 8% [17]. Additionally, the
collateral damage inflicted by long-term AZM exposure to pathogen susceptibility
to other antimicrobials is unknown.
In summary, the studies investigating AZM have shown that patients
receiving the drug have slight but significant improvements in lung function, most
notably measured by FEV 1% predicted. Additional improvements were
observed for number and time to an acute exacerbation of the disease, and
general patient quality of life. Because of these investigations, the Cystic
Fibrosis Foundation currently recommends chronic AZM therapy for patients over
the age of 6 years who are colonized with P. aeruginosa, as a method to improve
lung function [14]. A recent meta-analysis reviewed 8 different studies assessing
the effect of AZM in CF. Combining the data resulted in the drug inducing an
overall increase in FEV1% predicted [64]. This improvement was again more
pronounced in patients who were colonized with P. aeruginosa [64]. They also
showed that these patients were less likely to experience an acute exacerbation
of the disease, as well as a decrease in hospitalizations [64]. While it considers
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the potential benefit to be great, the CF Foundation considers the strength of the
data to only be fair. Thus it is currently classified as grade “B”, and not as a goldstandard therapy [14]. Improvements in the medications that patients with CF
take has lead to great improvements in the length of time that patients with CF
live, although the average age still is in the mid 30’s [11]. The consensus is that
AZM contributes to this success.
Others have also investigated the positive effects of AZM in other
pulmonary disorders. Notably, Beigelman et. al. showed that in an experimental
asthma model that mice treated with AZM displayed decreased influx of
macrophages and neutrophils, as well as a decrease in the influx of eosinophils
[65]. AZM treated mice also displayed fewer inflammatory cells around the
airways in their lungs [65]. Others have shown that AZM decreases acute
exacerbations and hospitalization in patients with COPD [66]. These findings
suggest a role for AZM in a wide variety of inflammatory and fibrotic lung
diseases, and further the importance of discovering the mechanism by which
AZM improves symptoms.
E. Cell signaling and macrophage phenotype

The NF-κB signaling pathway
The NF-κB signaling cascade is an important pathway that leads to the
up-regulation of many pro-inflammatory genes, and is a major transcription factor
that controls inflammation. A schematic of the NF-κB signaling pathway can be
seen in figure 1.2. Activation begins with stimulation from an external signal.
When macrophages are exposed to Gram-negative bacteria, including P.
aeruginosa, it is signaling through TLR4, which responds to binding to bacterial
LPS. The I kappa kinase (IKK) complex consists of three subunits, α,β, and γ.
The complex is next phosphorylated via TLR4 bound My88. Upon
phosphorylation of this complex, the complex phosphorylates IκB. In its
unphosphorylated form, IκB is bound to the p50 and p65 subunits of NF-κB in the
cytoplasm, and prevents these subunits from translocating to the nucleus. Upon
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phosphorylation, however, IκB is targeted for ubiquitination and destruction. With
the loss of its chaperone, NF-κB translocates to the nucleus, and upregulates the
expression of a wide variety of pro-inflammatory cytokines and other cellular
mediators [6-8]. The activation of the NF-κB cascade is one of the two steps
necessary for macrophages to be polarized to the M1 phenotype.
The interferon-γ STAT1 cascade
M1 macrophages additionally require signaling from IFNγ which has been
produced from Th1 polarized T cells (Figure 1.3). IFNγ binding signals through
the STAT1 signaling cascade. Briefly, IFNγ binds to both the type 1 IFNγr, and
the type 2 IFNγr. These receptors are pre-associated with either Janus
associated Kinase (JAK) 1 or 2. Upon IFNγ binding, these receptors oligomerize.
This allows JAK1 and JAK2 to phosphorylate both of the IFNγRs.
Phosphorylation of the IFNγRs creates binding sites on the IFNγR for STAT1.
Upon the binding of STAT1 to the cytoplasmic portion of the IFNγR, it is then
phosphorylated by JAK2. P-STAT1 then dimerizes, and is able to translocate to
the nucleus, and binds to IFNγ associated sequences. This induces the
expression of proteins associated with inflammation and the M1 macrophage
phenotype [4, 5].
Crosstalk between the two signaling cascades
For a macrophage to be polarized to the classically activated phenotype,
signaling from both of these pathways is necessary [67]. Stimulating
macrophages with either IFNγ or LPS is insufficient to achieve classical
activation. Likewise, if we stimulate cells with AZM alone, or with both IFNγ and
AZM, we are unable to shift the polarization of the macrophages to the M2
phenotype. Both cytokine signaling, as well as signaling from LPS are necessary
to achieve macrophage polarization [10]. It is reasonable to believe that these
cells are wired to require signaling from both of these pathways to polarize a
macrophage to an M1 phenotype in order to ensure that a strong inflammatory
and destructive cell type is not needlessly activated. However, there are
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increasing indications that the two pathways directly interact with each other,
rather than macrophage polarization being an additive effect of the pathways
(Figure 1.4).
Fong et. al. described a series of experiments suggesting a more direct
interaction between the two pathways. Utilizing Cre-recombinase technology,
they created mice that were deficient in IKKβ in either their airway epithelial
tissue, or in their myeloid cells (including macrophages). They then infected the
mice intranasally with group B streptococcus. As they expected, mice with IKKβ
selectively knocked out of their lung epithelial cells displayed a decrease in
inflammation, and increased proliferation of group B strep. More interestingly,
however, was the data from the mice deficient in IKKβ in their myeloid cells.
These mice actually had fewer bacteria in their lungs, indicating that they
responded well to clear the infection. They also displayed increased serum
levels of pro-inflammatory cytokines, as well as decreased arginase 1 mRNA in
their spleens. The cells also showed increased iNOS protein expression [68].
The authors suggested that IKKβ decreased M1 polarization. It is, however,
reasonable to assume that M2 polarization would also be increased. They next
found that IKKβ deficient cells displayed increased amounts of phosphorylated
STAT1, suggesting that activated IKKβ was inhibiting the activation of the IFNγ
signaling cascade, and that this was the mechanism by which they saw an
increase in M1 macrophage polarization in the IKKβ KO cells [68]. They suggest
that the crosstalk between the two pathways may exist as a mechanism by which
the body can prevent an overly-zealous M1 response to an infection, and prevent
any damage that may result from such a strong polarization.
IL4rα chain and M2 macrophage signaling
Inactive macrophages are polarized to an M2 phenotype via signaling
from interleukins 4 and 13 (IL4, IL13) produced by Th2 cells, mast cells, and
basophils [69-73]. What is interesting about alternative macrophage polarization,
however, is that both IL4 and IL13 share a common receptor chain for their cell
signaling (Figure 1.5). IL4 binds when the IL4rα chain and the common γc
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receptor chain dimerize, forming the type I receptor. The binding of IL13, on the
other hand, causes the IL4rα chain and the IL13rα chain to dimerize, forming the
type II receptor. IL4 can, however, also bind to the type II receptor as well as the
type I receptor [71]. Once either cytokine binds to either the type I or type II
receptor, it recruits JAK 1 to the intracellular portion of the receptor, and induces
phosphorylation. This allows STAT6 to bind to the receptor and be
phosphorylated. Once phosphorylated, STAT6 dimerizes, translocates to the
nucleus, and induces gene expression for genes that are upregulated in the M2
phenotype [71]. In our work, we will take advantage of the commonality among
IL4 and IL13 receptors, and employ an IL4rαKO mouse strain that lacks the
ability to respond to either cytokine. In using these animals, we will investigate
the impact of an absence of the M2 subtype upon the immune response to P.
aeruginosa infection.
F. Overview of the dissertation
With AZM, we have a commonly used medication in CF, with an unknown
mechanism of action. While we have previously shown that AZM is able to
polarize macrophages to an alternatively activated phenotype, the mechanism by
which this occurs is currently unknown. It has been shown that one potential
mechanism is via inhibition of NF-κB activation, although it is important to note
that this inhibition is markedly less than by corticosteroids [74]. There is also
evidence that there is cross-talk in the signaling pathways between the NF-κB
signaling cascade and the IFNγ signaling cascade. Specifically, it appears that
IKK-β, a molecule in the NF-κB cascade that inhibits activation of NF-κB, is also
able to inhibit phosphorylation and activation of STAT1. STAT1 is activated by
IFNγ, and once activated, it translocates to the nucleus and up-regulates the
production of classically activated macrophage makers. We show below that one
method by which AZM may polarize macrophages to the alternatively activated
phenotype is via increasing activation of IKK-β, without a resulting increase in
NFκB activation.
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We also are interested in what the role of increased M2 activation in the
lungs of patients with CF may mean in the long term for these patients. The
three major studies assessing AZM in CF have been conducted over a short time
period (3-12 months) [16, 18, 20]. The long term effects of the medication are
unknown. On first consideration, changing the polarization of macrophages
towards a pro-fibrotic phenotype is counterintuitive. Indeed, there is data
suggesting that in other fibrotic lung diseases a Th2 polarization leads to
alternatively activated macrophages, and results in increased scarring and
fibrosis [55]. Another possibility, however, is that by altering macrophage
polarization away from the M1 phenotype and towards the M2 phenotype, AZM is
able to blunt an overly zealous inflammatory response. By doing so, there will be
less damage to the lung parenchyma and peribronchiolar tissues, and a resultant
decrease in scarring and fibrosis in the lungs of these patients. This possibility is
also consistent with data showing that AZM treatment results in a decrease in
acute exacerbations of CF, as well as a decline in the amount of courses of
intravenous antibiotics that patients taking AZM experience [18, 20].
We hypothesize that AZM polarizes macrophages to an alternatively
activated phenotype via IKKβ dependent mechanisms. We also hypothesize that
by increasing M2 activation and decreasing M1 activation, AZM will improve the
response of mice and humans to pulmonary infections and CF. This will be
investigated through a variety of in vitro, in vivo, and human based studies.
In this dissertation, I will utilize a combination of cell culture, in vivo
experiments with mice, and human clinical research to test the mechanism and
importance of AZM dependent macrophage polarization in inflammatory lung
diseases. I will describe how AZM polarized macrophages alter the production of
fibrotic markers in a co-culture system of macrophages and fibroblasts.
Alternatively activated macrophages produce the precursors to fibrotic proteins,
and we hypothesized that macrophages polarized by AZM would increase the
production of fibrotic proteins in the co-culture system [2]. At first thought,
increasing the amount of a pro-fibrotic macrophage phenotype in a fibrotic lung
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disease such as CF seems counterproductive. Indeed, if a Th2 polarization in
the lungs is associated with a decline in outcomes in patients with CF, it would be
reasonable to suggest that a shift to an M2 phenotype would be associated with
a decline in outcomes in these patients [32]. A greater understanding of the
effector functions of AZM polarized macrophages will allow us to understand
whether the drug is polarizing macrophages to a novel phenotype, which may
function in a manner different than a traditional alternatively activated
macrophage.
Second, I will describe a potential mechanism by which AZM is able to
alter the polarization of macrophages, towards an M2-like phenotype. The
manner by which macrolide antibiotics are able to polarize to an alternatively
activated-like phenotype is currently unknown. A greater understanding of this
could provide future targets for medications that provide the immunomodulatory
effects of macrolides, without the need to place patients on antibiotics
chronically. I will additionally describe the role of M2 macrophages in the context
of acute infections with PA, and whether AZM is able to polarize macrophages to
the alternatively activated phenotype in a manner independent of IL4 and IL13
signaling, continuing the investigations into potential mechanisms by which AZM
is able to alter macrophage polarization. We have access in our laboratory to a
mouse strain that is deficient in the IL4rα chain. This receptor subchain is
necessary for both IL4 and IL13 to properly signal [2]. Macrophages from mice
deficient in the IL4rα chain display an impaired ability to be polarized to the
alternatively activated phenotype. We have used these mice to first characterize
the host response to P. aeruginosa infection with a lack of alternative
macrophage activation by the cytokines. These results describe the importance
of M2 macrophages in the response to intratracheal infection with P. aeruginosa.
Then, by treating mice deficient in the IL4rα chain with AZM, as well as
conducting ex vivo experiments on the cells collected from these mice, we were
able to assess whether the ability of AZM to polarize macrophages is dependent
on IL4 or IL13 signaling.
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Finally, I will describe a pilot human study that was conducted in
conjunction with our translational team of investigators. We collected sputum
samples from patients with CF, isolated mRNA, and performed quantitative realtime PCR on a variety of M1 and M2 proteins, as well as inflammatory and
fibrotic markers. We then correlated these gene markers to the clinical
parameters of the patients. We additionally performed principal component
analysis as a data reduction method to assess which gene markers are
correlated with each other. By doing this, we were able to place our subjects into
subgroups that are high or low in the various components, and assess whether
these patient groupings corresponded with certain clinical features. This allowed
us to determine if differences in gene expression were associated with clinical
outcomes or disease severity in subjects with CF. We hypothesized that
increased markers of M2 activation would be associated with AZM use and
declines in lung function in these subjects. An increased understanding of
macrophage associated gene expression in subjects with CF will lead to clinical
validation of our molecular and animal data, to provide a basis for future research
in therapeutic target discovery.
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Figure 1.1. Overview of arginine metabolism with macrophage polarization. M1
macrophages upregulate iNOS, leading to the conversion of arginine to citrulline
and nitric oxide. The produced nitric oxide is part of an oxidative burst in
macrophages, leading to destruction of internalized bacteria and localized
inflammation. M2 macrophages upregulate arginase. Arginase competes with
iNOS for arginine, and catalyzes arginine to urea and ornithine. Ornithine is a
necessary component of polyamines, which are then converted into fibrotic
molecules including collagen. Collagen production and incorporation into the
extracellular matrix is essential for tissue repair and fibrogenesis. Adapted from
[9, 10].
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Table 1.1. Function and markers of different macrophage phenotypes. Listed
are the macrophage phenotype, the stimulation necessary to polarize an inactive
macrophage to that phenotype, the function of the cell, surface markers,
functional markers, and the cytokines produced (adapted from [1-3]).
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Figure 1.2. Activation of the NF-κB signaling cascade. LPS binds to TLR4,
eventually leading to activation of the IKK complex. Upon activation of the IKK
complex, it phosphorylates IκB, leading to the destruction of IκB. IκB had been
bound to NF-κB, preventing it from translocating to the nucleus of the cell. When
NFκB translocates to the nucleus, it binds to DNA leading to the transcription of
genes associated with inflammation. Adapted from [6-8]
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Figure 1.3. Activation of the IFNγ-STAT1 cascade. IFNγ binds to the IFNγr,
leading to the recruitment of JAK1 and JAK2 to the receptor. The binding of
these two molecules allows STAT1 to bind to the receptor and become
phosphorylated. P-STAT1 dimerizes and translocates to the nucleus, leading to
the transcription of genes associated with M1 macrophage polarization. Adapted
from [4, 5].
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Figure 1.4. Crosstalk between the NF-κB and IFNγ-STAT1 cascade. Evidence
exists that IKKβ prevents STAT1 from being phosphorylated. It has been
hypothesized that this exists in part to eventually dampen a potent inflammatory
response. We will address the effect the AZM has upon IKKβ activation, leading
to the prevention of the IFNγ-STAT1 cascade.
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Figure 1.5. The IL4/IL13 signaling cascade. IL4 binds to dimers of the IL4rα
chain and the common cytokine gamma chain. IL13 binds to dimers of the IL4rα
chain and the IL13rα chain. JAK1is then recruited to the intracellular portion of
the receptor. This leads to recruitment and phosphorylation of STAT6. P-STAT6
then dimerizes and translocates to the nucleus, leading to the transcription of
genes associated with the M2 phenotype.
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Chapter 2: Azithromycin alters interactions between macrophages and
other cell types
A. Introduction
Chapter overview
To build upon previously generated data from our laboratory, we
expanded our investigation of the impact of AZM exposure, this time in a series
of in vitro experiments designed to test the impact the drug has upon
macrophage function. While our previous work has described the ability of AZM
to affect changes in macrophage polarization to an M2-like phenotype we still
have little knowledge as to the functional abilities of cells treated with the drug
[63, 75]. Because of the role that M2 cells play in orchestrating tissue
remodeling and fibrosis in damaged lungs [2], we set out to investigate the
interplay between AZM polarized macrophages and fibroblasts. This was done
to determine more about the phenotype of AZM polarized macrophages, and the
mechanisms by which macrophages interact with cells that produce fibrotic
proteins. We hypothesized that AZM polarized macrophages would interact with
fibroblasts in a co-culture system resulting in increased fibrogenesis.
Macrophage polarization: a brief overview
Macrophages are polarized to either the M1 or the M2 phenotype primarily
by cytokines produced from T cells [1-3]. Polarization to the M1 phenotype
requires signaling from the Th1 derived cytokine IFNγ, as well as a bacterial
signal such as LPS. The M2 phenotype requires signaling from IL4 and IL13,
which are produced primarily from Th2 polarized T cells [3]. It is important to
note that this polarization is not terminal, unlike T cells. If an M1 macrophage is
exposed to IL4/13, it can be shifted to the M2 phenotype, and vice versa.
Historically, when describing macrophages, it has been the classically
activated, or M1 phenotype that has been described. M1 macrophages are
phagocytic, and produce reactive oxygen species such as nitric oxide (NO). This
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allows these cells to rapidly and effectively internalize and destroy infectious
pathogens [35]. Macrophages are polarized to the M1 phenotype primarily from
Th1 T cell produced IFNγ [76, 77]. M1 macrophages additionally initiate
inflammation by producing inflammatory cytokines including TNFα, IL12, IL1 and
IL6 that draw other inflammatory cell types to the site of an acute infection [34,
36]. Classically activated macrophages additionally upregulate adhesion
molecules such as CCR7 that allow macrophages that have internalized bacteria
to then relocate to the lymph nodes, allowing presentation to the rest of the
immune system [3]. Both the influx of inflammatory cells, as well as the oxidative
burst caused by M1 macrophages leads to tissue damage, which over time
adversely effects lung function [37].
The host response to these bacteria is, in normal circumstances, under
tight control and regulation. However, the damage and destruction caused by
both pathogens and the immune system’s response to that damage then requires
considerable repair [78]. This repair is in part orchestrated by M2 macrophages
[2]. These macrophages are both anti-inflammatory and profibrotic. The M2
macrophage pattern of gene expression increases during the regulatory phase of
an acute infection in part to produce anti-inflammatory cytokines to prevent
excessive damage [79]. M2 macrophages additionally produce the precursors to
fibrotic proteins such as polyamines, leading to repair, fibrosis, and scarring [38].
These polyamines precursors are produced primarily from arginase dependent
catabolism of arginine to ornithine [80]. M2 macrophages additionally upregulate
expression of transforming growth factor beta (TGFβ). During fibrotic lung
diseases, increased TGFβ signaling results in chemotaxis of macrophages and
fibroblasts to the site of damage, secretion of growth factors, fibroblast
proliferation, and production of extracellular matrix molecules by fibroblasts [69,
81].
Transforming growth factor beta
Transforming growth factor beta (TGFβ) exists in three different isoforms,
TGFβ 1, 2, and 3. Among these, TGFβ 1 is the best characterized [81-83]. It is
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thought that all three isoforms exert similar effects [83]. TGFβ is secreted in an
inactive form from cells including macrophages, and is then attached to the
extracellular matrix. TGFβ activation plays a vital role in the generation of the
fibrotic molecules of the extracellular matrix, including fibronectin and collagen
[84]. It can then be cleaved to its active form by a variety of enzymes, including
elastases and metalloproteases [82]. Cells secrete large amounts of inactive
TGFβ, to allow the body to allow quick activation of the protein and facilitate cell
proliferation and fibrogenesis [82]. The secretion of inactive TGFβ, followed by
its eventual activation, allows the rapid marshalling of a large amount of activated
TGFβ in the face of a strong inflammatory response [82, 83].
Macrophage polarization by azithromycin
Our group has previously shown that AZM is able to polarize
macrophages to a phenotype resembling that of alternatively activated cells. We
have demonstrated this by assessing surface expression of markers of
macrophage polarization, functional proteins produced by each type of cell, and
the cytokine production profile [63]. What we do not know, however, is if AZM is
polarizing macrophages to the M2 phenotype, or to a novel phenotype that
contains unique characteristics. This possibility would explain in part why AZM
benefits patients with CF. At first glance, one might assume that shifting
macrophage gene expression to the pro-fibrotic M2 phenotype would be
detrimental for these patients. More cells with the pro-fibrotic M2 phenotype
could conceivably lead to increased scarring and fibrosis in the lungs of these
patients. If this was the case, we would expect AZM treatment to worsen the
functional decline for these patients. Instead, as noted in Chapter 1, it has been
shown that AZM modestly benefits patients with CF [16-18, 20].
We posit that by shifting the balance of macrophage polarization during an
acute flare away from the pro-inflammatory M1 phenotype and towards the antiinflammatory, pro-fibrotic M2 phenotype which will inflict less damage. A
decrease in the damage associated with acute infection would then require less
repair, and a resultant decrease in remodeling and fibrosis formation. This is
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especially true in the situation of CF, as the immune response in these patients is
exaggerated [32, 45]. By decreasing the amount of pro-inflammatory M1
macrophages in the lungs of these patients, AZM may be altering the “set point”
for an acute flare of the disease. That is, treatment with AZM may be preventing
an overly zealous immune response from initially occurring, while allowing the
immune system to still respond to the infection in a productive manner.
Data from our lab and others support this notion. In our mouse model of
Pseudomonas infection, when AZM induces an M2 phenotype to predominate,
neutrophil influx is blunted and peribronchiolar inflammation is lessened. We
additionally found greater macrophage influx into the lungs of these mice. The
cells that infiltrate into the lungs of these mice additionally produce fewer
inflammatory cytokines and more anti-inflammatory cytokines [75]. Herbert et. al.
have shown the importance of M2 macrophages in infections with Schistosoma
mansoni. They found that infected LysMcreIL4rα-/flox mice, which lack IL4 and
IL13 signaling on their macrophages, displayed 100% mortality, as compared to
wild-type controls, in which upwards of 75% survived the infection. They
determined that this increased mortality was due almost entirely to an overly
zealous immune response, characterized by NOS2 overexpression and impaired
egg expulsion [85]. Pesce et. al. found similar results with Schistosoma
mansoni. Intriguingly, however, they also found similar results with mice lacking
arginase 1 expression in their macrophages. They surmise that this is due to
arginase 1 depleting arginine, leading to a blunting of the CD4+ T cell response.
The addition of exogenous arginine similarly led to increased mortality, due
primarily to the recovery of the CD4+ T cell response in these mice [86].
Finally, AZM may be polarizing macrophages to a novel phenotype that is
anti-inflammatory, while not playing a role in fibrogenesis. In these experiments
we set out to determine if the phenotype of AZM polarized macrophages leads to
increased production of fibrotic proteins in a co-culture system with fibroblasts.
An increase in fibrogenesis in this system would suggest that AZM-polarized
macrophages and IL4/13-polarized macrophages function similarly. A greater
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understanding of the interplay between AZM-treated macrophages and
fibroblasts may lead to a greater understanding of the benefits of AZM treatment.
Production of fibrotic proteins and macrophages
Alternatively activated macrophages produce cytokines and other effector
proteins that lead to increased production of fibrotic proteins, including TGFβ,
fibronectin, and collagen in the lungs [3]. TGFβ signaling results in downregulation of the molecules that degrade the extracellular matrix, including the
matrix metalloproteases [81]. High expression of TGFβ has also been
associated with a decline in lung function in patients with CF [87]. Fibronectin
and collagen production is also upregulated, both in the macrophages as well as
the other cells present in the lung parenchyma. This results from byproducts of
arginase metabolism [80]. The enzyme arginase converts arginine to ornithine
and urea. Ornithine is a precursor to polyamines, which are, in turn, precursors
to matrix proteins including collagen [46, 88]. There is also considerable
evidence suggesting that M2 macrophages themselves produce fibronectin [89].
This fibronectin, once produced by either macrophages or fibroblasts, is
incorporated into the extracellular matrix, and provides strength and support to
the remodeled tissue [89]. We can thus test for the presence of fibrotic proteins
in vitro as we culture macrophages and fibroblasts together as a functional
surrogate, and determine whether AZM treatment results in a macrophage that is
pro-fibrotic. We hypothesized that AZM polarized macrophages would increase
the production of fibronectin in a co-culture with fibroblasts. We aimed to
determine the effect of AZM polarized macrophages on fibrogenesis by other cell
types.
B. Detailed methods
Co-culture of macrophages and fibroblasts
The mouse cell lines NIH/3T3 and J774A.1 (ATCC, Manassas, VA) were
used for all co-culture experiments. The NIH/3T3 line (ATCC #CRL-1568) is a
fibroblast cell line originally obtained from embryonic cultures of NIH Swiss mice
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[90]. The J774 (J774A.1, ATCC #TIB-67) cell line is an immortalized
macrophage cell line derived from BALB/cN adult mice [91]. Cells were grown in
RPMI 1640 media (Invitrogen, Carlsbad, CA), supplemented with 5% fetal calf
serum and 2x10-5M 2-mercaptoethanol at 37°C and 5% CO2. On day 0 of the
experiment, NIH/3T3 cells were added to 6 well plates at a density of 2.5 X 10 5
cells/ml, and allowed to incubate overnight. The media was removed the next
morning and replaced with 5 milliliters of new medium along with 5 X 10 4 J774
cells/1ml, and again allowed to incubate overnight. The next morning, cells were
stimulated by adding interferon-γ (R&D systems, Minneapolis, MN) (IFNγ)
(100ng/mL) and 2.5 X 105 P. aeruginosa, of the strain PA39018, a non-biofilm
producing strain obtained from ATCC (Manassas, VA). To study the effects of
the drug, designated wells additionally received 30μM AZM (Sigma Aldrich, St.
Louis, MO) (AZM). Some experiments additionally utilized a blocking antibody to
TGFβ at a concentration of 0.5μg/ml (R&D Systems, Minneapolis, MN). Cells
were incubated and harvested after 0, 6, 12, 24, 48, and 72 hours. At these time
points, cells were scraped and centrifuged, and 1mL of media was saved for
TGFβ analysis. Cells were washed, enumerated with trypan blue staining to
assess viability, and aliquots were taken for the arginase activity assay and qRTPCR. Supernatants and cell lysates were frozen at -80°C for later analysis,
including arginase activity and fibronectin quantification. Cell lysates were
suspended in either 150μl of RIPA buffer with Roche Mini-tablet protease
inhibitor cocktail, or in RNAlater (Applied Biosystems, Foster City, CA).
Quantification of arginase activity
Arginase activity was assessed via the protocols first described by
Corraliza et. al. [92]. This reaction assesses the concentration of urea in the
culture supernatant. Urea is a byproduct of the reaction converting arginine to
ornithine, and directly correlates to the concentration of arginase present. Briefly,
12.5 μL of 10mM MnCl2 in 50mM Tris HCl was added to 12.5 μL of cell lysates.
The arginase enzyme was activated by incubating the samples at 55°C for 10
minutes. A 0.5M arginine solution was then added, and the samples were
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incubated at 37°C. The reaction was terminated by the addition of 400 μL of an
acid solution consisting of H2SO4, H3PO4, and water at a ratio of 1:3:7. AlphaIsonitrosopropiophenone (9% w/v) dissolved in 100% ethanol was added, and
the mixture was then heated at 95°C for 45 minutes. All chemicals were
purchased from Sigma Aldrich (St. Louis, MO). Optical density was assessed
utilizing an ELx808-I microplate reader and a 490 nM filter (Bio-Tek instruments,
Winooski, VT). Readings were compared to a standard curve of known urea
concentrations, and then were then normalized both to protein concentration and
to cell counts. The values for arginase activity shown in this research are
expressed in terms of units of arginase activity. One unit of arginase activity is
responsible for the catalysis of 1 μmole of L-arginine to ornithine and urea per
minute at a pH of 9.5 at 37°C.
Fibronectin protein quantification
Cell culture supernatants were analyzed and the fibronectin
concentrations quantified by indirect ELISA. Samples were diluted in coating
buffer and incubated at 4°C overnight for adherence to the ELISA plate. Wells
were blocked, then incubated with an antibody specific to MMP-9 (Abcam,
Cambridge, MA), followed by an anti-rabbit HRP conjugated secondary antibody.
Wells were analyzed by OD reading at 450nm, using OptEIA detection reagents
(BD, ). Readings were compared to a standard curve using MMP-9 or fibronectin
recombinant protein.
Surface marker expression
Cells were incubated with fluorescently-labeled monoclonal antibodies to
both identify macrophages and detect surface receptors indicative of alternative
activation. Antibodies specific for mouse mannose receptor (MR) (Serotec,
Raleigh, NC), and CD11b (BD bioscience, San Jose, CA) were used. The cells
were washed before and after antibody incubation with azide-containing buffer.
Cells were analyzed by flow cytometry using a BD LSRII Flow Cytometer System
(BD Biosciences, San Jose, CA) under the direction of a dedicated operator.
33

Fifty-thousand events per sample were routinely collected, and data was
analyzed using FlowJo software package (Tree Star, Ashland, OR).
qRT-PCR
RNA was isolated using RNeasy mini kits (QIAGEN, Valencia, CA).
Isolated RNA was quantified using a Nanodrop 2000 (Thermo Fisher Scientific,
Wilmington, DE). Reverse transcription was performed on equal amounts of
RNA utilizing Taqman Reverse Transcriptase Reagents (Applied Biosystems,
Foster City, CA) according to manufacturer’s protocols. Quantitative real-time
PCR was initiated utilizing Taqman gene expression arrays for murine TGF-β1
and GAPDH using an ABI Prism 7000 (Applied Biosystems, Foster City, CA).
Preparation of P. aeruginosa impregnated agarose beads and mouse
infection
To ensure a viable infection, P. aeruginosa of the biofilm producing strain
M57-15 was impregnated in agarose beads. Bead preparation was an
adaptation of previously described methods [93, 94]. In the absence of agarose
beads, mice are able to quickly clear infections with P. aeruginosa. Impregnation
in agarose beads allows for a more chronic, stable infection, and leads to greater
cellular infiltration and weight loss in these animals [94]. In brief, P. aeruginosa
was first grown to late log or early stationary phase in TSB. The organism was
then added to a 2% agarose solution in PBS. This solution was then combined
with warm mineral oil, and quickly cooled. The beads were then washed twice in
solutions of deoxycholic acid to remove the mineral oil, followed by 6 washes
with PBS. Beads were resuspended in PBS, and an aliquot was collected,
homogenized, and plated on TSB agar plates to determine the number of viable
bacteria in the beads.
Tissue processing and cell phenotyping
Lungs were minced in RPMI and digested in 50U/ml DNase (Sigma
Aldrich, St. Louis, MO) and 1mg/ml collagenase A (Sigma Aldrich, St. Louis,
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MO). After incubation for 1 hour, cells were pushed through a mesh screen.
Red blood cells were lysed using a hypotonic salt solution. Cells were washed
twice, enumerated, and transferred to 5ml round bottom polystyrene tubes for
flow cytometry analysis. Aliquots of cells were collected and lysed in RIPA buffer
to protect protein in the samples. These cells were then frozen at -80° C for later
analysis. An additional aliquot was incubated at 37°C with 5% CO 2 for 2 hours
with 50ng/ml phorbol 12-myristate 13-acetate (PMA) and 1μg/ml ionomycin,
followed by 2 hours with 10 μg/ml brefeldin A to stimulate production of
intracellular cytokines for flow cytometry analysis.
Cells were stained for flow cytometry for markers of general cell
phenotype, as well as markers of macrophage phenotype and both inflammatory
and anti-inflammatory cytokines. Three different flow cytometry panels were
assessed for each type of mouse. The first panel for the C57bl/6 mice consisted
of CD11b-PECy5 (Serotec, Raleigh, NC), a marker found on macrophages, GR1PECy7, a marker of neutrophils, MR-PE, a marker of M2 macrophages (Serotec,
Raleigh, NC), CD80-FITC, a marker of M1 macrophages, and biotinylated I-A[b]
MHC II, a protein that is increased in expression with classical macrophage
activation. Panel 2 consisted of CD11b-APC, CD11c-PECy7 (BD Bioscience,
San Jose, CA), a marker of resident macrophages and dendritic cells, CD4PECy5, a marker of CD4+ T-cells, GR1-FITC, and CD19-PE, a marker of B-cells.
Panel 3 consisted of CD11b-PEcy5, CD11c-PECy7, TNFα-FITC, biotinylated
TGFβ, and IL10-PE. Secondary staining was performed when appropriate
utilizing a streptavadin conjugated to APC. All antibodies were purchased from
BD bioscience (San Jose, CA), unless otherwise stated. Cells were analyzed
with utilizing a FACSCaliber Flow Cytometer (BD Biosciences, San Jose, CA)
with a dedicated operator. Greater than 50 thousand events per sample were
routinely examined. Flow cytometry analysis was performed utilizing FlowJo
(Treestar, Ashland, OR).
Statistical analysis
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Results are reported as mean ± SD and compared using GraphPad Prism
(GraphPad Software, La Jolla, CA). A repeated measures ANOVA with Tukey’s
multiple comparison test were utilized for time courses. For some data, T-tests
were used to compare means between groups. Non-linear regression utilized
the least squares method for fit. Differences in survival were assessed utilizing a
log-rank (Mantel-Cox) test. Unless otherwise stated, significance was deemed to
be a p value <0.05.
C. Results and discussion
Azithromycin increases markers of the M2 phenotype in the presence of P.
aeruginosa when macrophages are co-cultured with fibroblasts
We first assessed markers of M2 activation in the co-culture system, to
ensure that AZM was able to achieve this polarization in the presence of both a
second cell type, as well as in the presence of a live P. aeruginosa, as opposed
to bacterial LPS [63]. We measured arginase activity in the lysates from cocultured cells over time stimulated with the live organism in the presence of IFNγ
as described in the Methods section (Figure 2.1). We found that arginase activity
was significantly higher in the cells treated with AZM, as compared to the cells
that did not receive AZM after 24, 48, and 72 hours in culture. Arginase
concentrations decreased as expected when the organism was introduced, as
this shifts macrophages into a pro-inflammatory state. AZM exposure appeared
to cause stabilization in production, so that by 24 hours the concentration of
arginase rebounded to a significantly higher level than the control wells. We next
assessed the impact of AZM upon the numbers of cells expressing both CD11b
and MR. Cells positive for CD11b represent the macrophage cell line, as
fibroblasts are negative for this surface protein, and MR is a representative
protein with a trend towards upregulated expression during alternative
polarization (Figure 2.2). In concordance with the increases observed in
arginase activity, we found that cells treated with AZM displayed increased MR
expression at 24, 48, and 72 hours. Both the arginase and mannose receptor
data suggest that AZM is also able to polarize macrophages toward an M2-like
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phenotype in the presence of viable P.aeruginosa, and the fibroblast cell line.
This confirmation allowed us to move forward with the co-culture experiments
confident that AZM is affecting the changes that we have observed previously in
J774 cultures.
Azithromycin increases TGFβ activation
We first assessed the concentration of activated TGFβ in the lysates from
our co-culture system (Figure. 2.3 A.). The assay that we utilized non-specifically
measures activation of all 3 isoforms. Here we found that after 24 and 48 hours
of culture with P. aeruginosa in the presence of IFNγ, there was a marked
increase in the amount of active TGFβ found in the supernatants when AZM was
present (p<0.05 and p<0.01, respectively). We then assessed the ratio of
activated TGFβ to total TGFβ in the system (Figure. 2.3 B). We found that the
ratio was higher in the cells that were treated with AZM as compared to cells that
did not receive AZM at 24 hours (p<0.05). Intriguingly, in the cells that received
IFN and LPS there were essentially no differences in the active TGFβ to total
TGFβ ratio across the various timepoints. It was only in the cells treated with
AZM that we observed a marked increase in TGFβ activation. We finally
assessed TGFβ-1 gene expression via quantitative real-time PCR (Figure. 2.3 C)
over time after P. aeruginosa stimulation. While we observed a marked upregulation in TGFβ gene expression in both the IFN and IFN+AZM groups after 6
hours, there was then a down-regulation of TGFβ gene expression in both
groups. There was less of a decrease in TGFβ-1 gene expression in the cells
that received AZM, as compared to the cells that did not receive AZM, although
neither individual timepoint differences nor differences of the entire curve were
statistically significant.
This data suggests that AZM exerts a considerable effect on TGFβ
activation in our co-culture system. We additionally observed trends towards
increased TGFβ-1 gene expression in the co-culture system in cells treated with
AZM. While the exact mechanism by which TGFβ activation in our co-culture
system is increased is yet unknown, we have hypothesized that AZM may be
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increasing expression of enzymes that activate TGFβ. The matrix
metalloproteases (MMPs) are molecules that play an important role in
extracellular matrix homeostasis by cleaving the proteins in the extracellular
matrix facilitating matrix turnover. As part of the facilitation of this turnover,
MMP-9 additionally plays a role in the cleavage and activation of matrix bound
TGFβ, leading to new fibrogenesis [95]. Indeed, work done by others in our
laboratory has shown that AZM up-regulates expression of MMP 9, and therefore
we have hypothesized that this up-regulation is responsible, at least in part, for
increased TGFβ activation. While others have shown that the production of
inactive TGFβ is upregulated in M2 macrophages, we did not observe significant
differences, only trends in gene expression of TGFβ-1. Three possibilities
present themselves. First, we may not have had adequate power to detect
significant differences. Second, we only assessed production of TGFβ-1, and did
not assess gene expression of any other TGFβ isoforms. Had we assessed
these other isoforms, we may have detected significant differences in gene
expression with AZM treatment. Finally, AZM appears to not be increasing
TGFβ gene expression in our macrophages. This would represent a difference
between macrophages polarized to the M2 phenotype via IL4/13 and
macrophages polarized to the M2 phenotype via AZM. In IL4/13 dependent M2
macrophage polarization, TGFβ production is upregulated [38].
Azithromycin results in increased fibronectin production in co-cultured
macrophages and fibroblasts
We then assessed the concentration of the fibrotic protein fibronectin in
the co-culture system (Figure 2.4). Fibronectin is secreted by macrophages and
fibroblasts, and we would expect expression to be increased with the addition of
AZM [81]. This is in fact what we observed. After culturing cells in the presence
of IFNγ and P. aeruginosa, significantly higher fibronectin concentrations were
measured in the cell lysates at 12 and 24 hours with the addition of AZM (p<0.01,
0.05, respectively). Separate controls utilizing only J774 and NIH/3T3 were
additionally utilized to confirm that changes in fibronectin expression was due to
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effects between the two cell types, instead of AZM directly causing fibrogenesis
(Figure 2.4 B., C.). This suggests that macrophages polarized to the M2
phenotype via AZM lead to increased fibronectin production, both from the
macrophages and the fibroblasts in the co-culture system. We surmise that this
occurs for two reasons. First, we believe that AZM stimulated macrophages are
increasing their production of inactive TGFβ. This is confirmed by our qRT-PCR
data showing that at our later timepoints there is more TGFβ-1 mRNA in
conditions treated with AZM. Others have found similar findings with different coculture systems [54]. Second, we believe that the AZM treated macrophages are
additionally upregulating metalloproteases including MMP, leading to increased
activation of the inactive TGFβ in the extracellular matrix. The combination of
increased TGFβ production and increased activation of the TGFβ that is
produced is responsible for increased fibrogenesis by the fibroblasts in the coculture system.
The increase in fibronectin concentration that we found suggests that AZM
polarized macrophages function in a manner similar to M2 macrophages. We
have previously shown that AZM polarized macrophages display surface markers
and functional proteins consistent with the M2 phenotype [63]. Here we
demonstrate that AZM polarized macrophages exert a similar effect on
fibroblasts and fibrogenesis as has been reported by others [55, 96]. This further
supports the notion that AZM polarized macrophages function in a similar
manner to that of M2 cells, rather than a novel phenotype.
Blockade of TGFβ activity eliminates azithromycin dependent fibronectin
expression in co-cultured macrophages and fibroblasts.
We finally repeated these experiments additionally utilizing a blocking
antibody to TGFβ. Addition of the blocking antibody eliminated the differences in
fibronectin concentrations in the cell lysates between conditions treated with AZM
and those that did not receive AZM (Figure 2.5). This further mechanistically
narrows the mechanism by which AZM treatment of macrophages results in
increased fibrogenesis. It appears that increased activation of macrophage39

derived TGFβ is responsible for the increases in fibroblast derived fibrogenesis in
the co-culture system.
Azithromycin results in increased survival in C57bl/6 mice infected with P.
aeruginosa
We next assessed the role of AZM in C57bl/6 mice infected with P.
aeruginosa. We wanted to assess the importance of this AZM dependent
macrophage polarization in the context of a complete immune response, to
further the work done in our in vitro system. We examined the effect of AZM on
weight loss, survival, and bacterial colony counts in our C57bl/6 mice that were
treated with AZM. We first assessed weight loss between mice that did or did not
receive AZM (figure Figure 2.6 A.). Infected mice lost weight consistently over
the first 3 days after infection, after which time weight was regained over the
remainder of the study period. Statistically significant weight loss was noted in
both infected groups of mice as compared to a sham-infection control group on
days 1 through 3. No statistically significant difference was observed as a result
of AZM treatment between groups of infected animals, although the mice treated
with AZM displayed a non-significant trend of gaining weight back more quickly
around day 7 post-infection. We then assessed differences in survival for
animals infected with P. aeruginosa incorporated into agarose beads that did or
did not receive AZM (Figure 2.6 B.). This data represents pooled data from
multiple iterations of our infections. We found that mice treated with AZM had a
significantly higher rate of survival compared to mice that did not receive the drug
(p=0.0195). Only a small amount of our AZM treated animals died or had to be
sacrificed early in accordance with our protocol. In animals that did not receive
AZM, however, we observed a death rate approaching 50%. Finally, we
assessed the number of bacteria present in the lungs of these animals (Figure
2.6 C.). Importantly, we found no differences in the number of bacteria in the
lungs of the mice between the two groups. The bacterial burden, in fact, did not
differ at any timepoint examined during any experiment performed, suggesting
that AZM does not exert an effect on bacterial clearance in this infection model.
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Azithromycin increases monocyte influx and decreases neutrophils influx
We then assessed the of the characteristics of cellular influx in both the
alveolar space (lavages) and lung digest samples in mice infected with P.
aeruginosa incorporated into agarose beads, to determine if AZM treatment had
an effect. In the lung digests, we found a trend towards an increase in the
number of cells present in the lungs of animals treated with AZM at day 14 of the
experiment (p=0.067) (figure 2.7 A.) [75]. Expression of the protein CD11b was
evaluated as a marker of monocytes that were elicited into the lungs postinfection. The marker is highly expressed on infiltrating macrophages. We found
significantly more CD11b+ cells in the lung lavages on day 7 post-infection
(p=0.006), indicating an increase in the number of infiltrating monocytes present
in the lungs of these mice (figure 2.7 B.). Finally, we found that AZM treatment
resulted in decreases in the numbers of neutrophils present in the lungs of these
animals, both in the lung digest at day 7 (p=0.002) (figure 2.7 A.) and a trend
towards a decrease in the numbers of neutrophils present in the lung lavage
samples. The number of CD4+ T cells in the lung parenchyma increased
similarly through day 7, but by day 14 there was a significantly higher number of
CD4+ T cells in the mice treated with AZM (p<0.001). Similarly, the number of
CD4+ T cells that infiltrated the alveolar space was higher in mice treated with
AZM on day 7 post-infection (p=0.004). This data shows that AZM appears to be
altering the types of cellular influx present in the lungs of these mice.
Azithromycin shifts macrophage polarization in the lungs to the M2
phenotype
Because CD11b+ cells displayed differences in migration characteristics
with AZM exposure, we analyzed the activation characteristics of these cells.
(Figure 2.8 A.) [75]. When examining the surface protein expression of cells that
were CD11b+GR1- (monocytes), MR expression was consistently increased in
the AZM treatment group on day 7 post-infection (p=0.003). Conversely,
expression of the classical activation marker CD80 was decreased in the cells in
the lung digest in mice receiving AZM (p=0.002). Other surface receptors
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including CD23, CCR7, and MHC II were up-regulated post-infection on
CD11b+Gr-1– cells in a similar manner between the treatment groups. We
additionally observed increased arginase expression in the mice that received
AZM on day 7 of the experiment (p<0.001) (Figure 2.8 B.). This data further
confirms the findings that we have previously observed in vitro concerning the
ability of AZM to polarize macrophages to an alternative-like phenotype.
Azithromycin alters the influx of inflammatory cells to the lungs of C57bl/6
mice
Patients with chronic inflammatory lung conditions who are infected with P.
aeruginosa are susceptible to the development of inflammation and fibrosis
surrounding the small airways. To determine the extent to which AZM affected
the damage to the lung parenchyma, histology sections were prepared from
lungs isolated at each timepoint. Evaluation using H&E staining revealed
inflammatory changes in both AZM-treated and -untreated groups at days 3 and
7 post-infection. Day 7 sections from AZM-treated animals were suggestive
however of a decreased amount of interstitial inflammation surrounding diseased
bronchioles (Fig. 2.9). In addition, on day 7 post-infection a systematic
examination of the sections showed that inflammatory cells surrounding
bronchioles mainly consisted of monocytic cells in mice that received AZM, as
opposed to the neutrophil-dominated infiltrates in the control group (Figure 2.9).
This finding corresponds to the flow cytometry data presented, and in addition
confirms that a majority of the CD11b+GR1+ cells induced by AZM treatment
were macrophages.
D. Conclusions
General conclusions
Here we present data showing that AZM increases arginase activity and
MR expression on macrophages when co-cultured with fibroblasts and stimulated
with live P. aeruginosa. While we expected to observe these changes based on
our previous data, this work proves that this polarization occurs in a similar
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manner when using either LPS or live bacteria. We further observed significant
increases in fibronectin levels in the co-culture system in cells that were treated
with AZM. The increases in TGFβ activation we observed, as well as the trend
towards increases in TGFβ-1 gene expression suggest that AZM polarized
macrophages result in increased fibrogenesis by fibroblasts in the co-culture
system. As part of this work, we have also shown that AZM additionally
upregulates proteins that activate TGFβ, including MMP-9. We hypothesize that
the increase in TGFβ that we observe is due at least in part to upregulation of
MMP9 by macrophages. We believe that this upregulation then results in
increased activation of TGFβ, leading to increases in fibrogenesis from the
fibroblasts in the co-culture system. Other work in our laboratory has also
assessed MMP9 expression in the co-culture system with the addition of the
TGFβ blocking antibody. As expected, the addition of the TGFβ blocking
antibody exerted no effect on MMP9 expression, showing that the effects of
TGFβ in the system are focused on fibrogenesis. This data will be presented in a
future graduate dissertation. We cannot, however, eliminate the possibility that
AZM may be altering other activators of TGFβ, including plasmin, cathepsin D, or
calpain [83].
We further found that AZM exerted considerable effects on macrophage
polarization and survival in our C57bl/6 mouse infection model. We found that on
day 7 of the infection there was a marked shift in macrophage polarization
towards the M2 phenotype in mice treated with AZM, and that mice treated with
AZM were significantly less likely to die from their P. aeruginosa pneumonia.
This shows the significance of macrophage polarization in the response to
pulmonary P. aeruginosa infections. We hypothesize that this improvement is
due to a blunting of the initial potent inflammatory response that occurs in the
context of infection with P. aeruginosa.
Limitations
The system that we utilized is, by its very nature limited. Our co-culture
system was designed to approximate the processes that occur in the lungs
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during an acute infection. Extrapolations are difficult to make to in vivo systems,
as well as to project the clinical relevance of the findings to apply to human
therapies. With this limitation in mind, however, we still believe that there are
considerable comparisons that can be made between the two systems.
The utilization of live bacteria in some of these experiments also
complicates the data. The number of bacteria present in our wells greatly
increases over the course of the experiment. At the later timepoints the number
of bacteria overwhelms the cells in the culture, leading to widescale death of cells
in the system. This may be influencing the results that we see at our later
timepoints. Importantly however, the presence of AZM did not alter the growth of
the bacteria or the rate of cell death between groups.
In our in vivo experiments, we additionally were unable to collect any data
from mice who died or were sacrificed according to protocol. The absence of
these animals may be skewing the data that we collect. That is, we are unable to
determine the phenotype and extent of infiltrating cells into the lungs of the
animals that have died. This may result in us observing differences that were not
there, or missing significant differences between the two treatment groups.
In chapters three and four we will further examine the importance of AZM
dependent M2 polarization in vivo. We will examine the importance of M2
macrophage polarization with mice with P. aeruginosa pneumonia, as well as in
humans with CF.
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Figure 2.1. Arginase activity in co-culture treated with 30 μM AZM and P.
aeruginosa. NIH/3T3 were cultured overnight in RPMI + 5% FCS at 37°C with
5% CO2. The next morning J774 cells were added, and the cells were
incubated together overnight. The next morning and IFNγ, P. aeruginosa (PA),
and AZM were added. Cells were harvested at 0, 6, 12, 24, and 48 hours, and
cell lysates were utilized for the arginase activity. Graph shows arginase
activity, a measurement of arginase concentrations, in the lysates preparations.
Data shows mean ±SD, with each sample run in triplicate. Data were analyzed
by two-way ANOVA with a Bonferroni’s post-test. ** indicates a p value of <
0.01. *** indicates a p value of < 0.001. Data representative of three replicates.
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Figure 2.2. Alternatively activated macrophages in a co-culture system treated
with AZM and P. aeruginosa. NIH/3T3 were cultured overnight in RPMI +5 %
FCS at 37°C with 5% CO2. The next morning J774 cells were added, and the
cells were incubated together overnight. The next morning IFNγ, P. aeruginosa
(PA), and AZM were added. Cells were harvested at 0, 6, 12, 24, 48, and 72
hours, and cell lysates were utilized for the arginase activity. Macrophages were
analyzed by flow cytometry for surface expression of mannose receptor. Data
were analyzed by two-way ANOVA with a Bonferroni’s post-test. ** indicates a p
value of < 0.01. Data representative of two replicates.
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Figure 2.3. TGFβ expression in a co-culture system. NIH/3T3 were cultured
overnight in RPMI + 5 % FCS at 37°C with 5% CO2. The next morning J774 cells
were added, and the cells were incubated together overnight. The next morning
and IFNγ, LPS, and AZM were added. Cells were harvested at 0, 6, 12, 24, and
48 hours, and cell lysates were collected. Panel (A) Activated TGF-β
concentrations in the culture supernatant as measured by TGFβ 1 Emax
ImmunoAssay System. (B) Ratios of active over total TGF-β were normalized to
time zero. (C) PCR analysis of TGF-β mRNA was normalized to GAPDH
expression in each sample, and then normalized to expression of TGF-β at time
zero. Data were significant to a p value < 0.05. All data were analyzed with twoway ANOVA with Bonferroni’s post-test. * equals p value < 0.05, ** p value <
0.01, *** p value < 0.001. Data representative of three replicates.
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Figure 2.4. Fibronectin expression in the co-culture system. (A) NIH/3T3 were
cultured overnight in RPMI + 5% FCS at 37°C with 5% CO2. The next morning
J774 cells were added, and the cells were incubated together overnight. The
next morning and IFNγ, P. aeruginosa (PA), and AZM were added. Cells were
harvested at 0, 6, 12, 24, and 48 hours, and cell lysates were utilized for the
arginase activity. (B) Fibronectin concentrations with just J774 cells, (C)
Fibronectin concentrations with just NIH/3T3 cells. Fibronectin concentration in
the cell lysate was determined by indirect ELISA. Data represents mean ± SD.
*** equals a p value <0.001 while * equals a p value < 0.05. Results were
normalized to μg protein in each sample. Data representative of three
replicates.
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Figure 2.5. Fibronectin expression in the co-culture system in the presence of a
TGFβ blocking antibody. NIH/3T3 were cultured overnight in RPMI + 5% FCS at
37°C with 5% CO2. The next morning J774 cells were added, and the cells were
incubated together overnight. The next morning and IFNγ, P. aeruginosa (PA),
AZM, and a blocking antibody to activated TGFβ were added at a concentration
of 5μg/ml. Cells were harvested at 0, 6, 12, 24, and 48 hours, and cell lysates
were utilized for the arginase activity. Fibronectin concentration in the cell lysate
was determined by indirect ELISA. Results were normalized to μg protein in
each sample. Data representative of three replicates.
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Figure 2.6. Weight loss, survival, and infection burden over time in C57bl/6
mice. Mice were infected with P. aeruginosa impregnated agarose beads,
and received either 3.2 mg AZM daily or vehicle control beginning 4 days
before infection. One group of mice additionally received AZM, but only a
sham infection. 4 mice were sacrificed at each timepoint (A) percent weight
loss from baseline. (B) Percent survival from multiple pooled replicates of the
experiment. (C) Number of bacteria present in the lungs of these mice.
Significant differences (p<0.05) are indicated (*), and are representative of
the results for multiple experiments.
Copyright © 2010, American Society for Microbiology. All Rights Reserved
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Figure 2.7. Immune cell infiltration into lungs of P. aeruginosa infected
mice treated with AZM. Mice were infected with agarose beads containing
between 105 and 106 P. aeruginosa. Immune cell subtypes were quantified
by flow cytometry in the (A) lung digest or (B) lung lavage. Panels
represent total cells, CD11b+ cells (infiltrating macrophages) (nonlymphocyte gate), CD11c+ cells (resident macrophages) (non-lymphocyte
gate), neutrophils and infiltrating monocytes (CD11b-GR1+), and CD4+ T
cells (lymphocyte gate). Mean values ± SD are depicted. Significant
differences (p<0.05) are shown for differences between groups at the same
time point (*), and between groups when all animals were taken into
account across time points (†)
Copyright © 2010, American Society for Microbiology. All Rights Reserved
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Figure 2.8. Characteristics of macrophage activation status in AZM treated
C57bl/6 mice infected with P. aeruginosa. (A) Surface staining via flow
cytometry of markers of M2 activation (MR, CD23), or M1 activation (CD80,
CCR7, and MHC II) on cells that were CD11b+. (B) Fold increase from
baseline in arginase activity. Samples from each mouse group were pooled
and run in triplicate. Mean values ± SD are depicted, and samples were
deemed statistically significant with a p<0.05 (*)
Copyright © 2010, American Society for Microbiology. All Rights Reserved
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Figure 2.9. Lung sections from mice which are day 7 post P. aeruginosa. H & E
stains of lung sections that received (A) AZM or (B) vehicle control.
Magnification increases from top to bottom, with bars representing 50, 25, and
12.5 μm, respectively. Pictures represent a predominately monocytic cellular
infiltration into the lung parenchyma in AZM-treated animals (triangular pointers),
while in control mice the inflammatory response is dominated by neutrophils
(arrows). Br=bronchiole, V=venule.
Copyright © 2010, American Society for Microbiology. All Rights Reserved
Copyright © Theodore James Cory 2011
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Chapter 3: Mechanistic investigations into the anti-inflammatory effects of
azithromycin
A. Introduction
Chapter overview
We next investigated aspects of the mechanism by which AZM polarizes
macrophages to the M2 phenotype, and the importance of this polarization in the
host response to P. aeruginosa infection. The mechanism by which AZM affects
the shift in macrophage polarization to an M2-like phenotype is as yet unknown.
It has previously been shown that AZM decreases the activation of NF-κB
signaling [74, 97]. NF-κB has been shown to play an important part in both the
innate and adaptive immune system, leading to inflammation and cell death [7,
98]. Activation of NF-κB leads to the up-regulation of a wide variety of proinflammatory molecules including the cytokines IL-6, IL1-β, and TNFα; and
enzymes including iNOS and COX-2 [7]. Some have hypothesized that by
inhibiting activation of NF-κB, AZM decreases the net inflammatory response to
pathogens in CF [74, 97]. It has been shown that through this mechanism of NFκB inhibition, AZM decreases the production of pro-inflammatory cytokines [97].
Cheung et. al. utilized a cell line with a stably expressed reporter gene and found
that the IC50 for AZM in the system was approximately 56μM [74]. Cigana et. al.
observed that AZM exerted similar effects with DNA binding to NF-κB in CFTR
deficient cell lines. They additionally found that AZM treated cells produce less
TNFα [97]. While these hypotheses may help to explain the beneficial effects of
AZM in patients with CF, it does not by itself explain a mechanism by which AZM
is able to polarize macrophages away from the M1 phenotype, and towards the
M2 phenotype. We hypothesized that AZM achieves this via inhibition of STAT1
through cross-talk from NF-κB signaling mediators.
To extend our cell culture experiments, we assessed the ability of AZM to
alter macrophage phenotype in mice. Specifically, we were interested in
assessing the ability of AZM to polarize macrophages to an alternatively
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activated phenotype in vivo, and whether this polarization occurs independent of
the traditional mechanisms necessary to achieve M2 polarization. As shown in
Chapter 2, AZM can polarize macrophages to an alternatively activated
phenotype in C57Bl/6 mice infected with P. aeruginosa. The drug alters the
cellular influx into the lung parenchyma and alveolar space during acute infection
to a more monocytic, and less neutrophilic profile, and controls the inflammatory
response observed [75]. We were curious if we would see a similar effect in
mice that lack the IL4rα chain, which are unable to polarize to an M2 phenotype
via IL4 or IL13 signaling. Several groups (including our own studies) have
demonstrated the impact that AZM exerts upon cytokine expression [37, 63, 99,
100]. However, due to data presented below in the first half of this chapter
concerning AZM’s effect on IKKβ activation, we believe that cell signaling
mechanisms are altered such that the effects of the drug are independent of the
downstream effects of cytokines. It would be reasonable to surmise that the
ability of AZM to polarize macrophages is due to alterations in cytokine
production, or to effects on T cells. However, we have shown in vitro that AZM
exerts direct effects on macrophages, rather than on the milieu of cytokines in
the lungs [63]. In the second half of this chapter, we will address the hypothesis
that azithromcyin polarizes macrophages to an M2 phenotype independent of
IL4rα function.
Cell signaling and macrophage polarization: A brief overview
Macrophages are polarized to one of the two traditional phenotypes via
signaling from three distinct pathways. M1 activation requires signaling from
both the IFNγ and TLR4 signaling cascades. IFNγ dependent signaling results in
phosphorylation and dimerization of STAT1. These dimers then translocate to
the nucleus of the cell, and induce inflammatory gene expression [4, 5]. In M1
activation, this signaling pathway synergizes with the NF-κB pathway, leading to
the up-regulation of pro-inflammatory molecules. The NF-κB pathway begins
with LPS binding to TLR4. This binding leads to phosphorylation of the IKK
complex, including phosphorylation of IKKβ. Activation of IKKβ leads to the
55

phosphorylation, ubiquitination, and the destruction of IκB. The destruction of
IκB, which sequesters NF-κB, then allows NF-κB to translocate to the nucleus of
the cell. This then results in up-regulation of pro-inflammatory cytokines such as
IL6, IL1β, and TNFα. Additionally, pro-inflammatory molecules including iNOS
and COX-2 are up-regulated [6-8].
Alternative polarization utilizes a different signaling pathway for its
activation. M2 polarization begins with the binding of either IL4 or IL13 to their
respective receptors. Interestingly, both the IL4r and the IL13r utilize, in part, the
same receptor subchain, the IL4rα chain. Activation of either the IL4r or the IL13r
results in phosphoryaltion and dimerization of STAT6. Upon activation, STAT6
then translocates to the nucleus of the cell and up-regulates genes associated
with anti-inflammatory processes and the M2 phenotype [69-73]. Many groups
report being able to polarize macrophages to the M2 phenotype only by
stimulating with either IL4 or IL13 [1, 34]. In our lab, we additionally utilize
stimulation from LPS to polarize macrophages to the M2 phenotype. We use this
method because we learned that AZM is unable to polarize macrophages to the
M2 phenotype in inactive macrophages. Signaling from both IFNγ and LPS is
required to be able to achieve this polarization to the M2 phenotype with AZM.
This characteristic of AZM provides basis of support for our hypothesis that the
mechanism of the drug’s ability to polarize cells lies in its interference with these
signaling cascades.
IL4rα chain KO mice
We utilized the mouse strain Balb/c-Il4ratm1Sz/J (IL4rαKO) for these
experiments. These mice are on a Balb/c background, and lack the IL4rα chain
on all cell types. They have been shown to display a decreased Th2 response,
and have a markedly impaired Th2 polarization in response to infections with a
wide variety of pathogens [101-103]. Most of the work performed with these
mice has examined their ability to respond to pathogens that induce a robust Th2
response, most notably parasites. The IL4rαKO mice are less able to clear
infections with the parasite Brugia malayi, an organism in which a strong Th2
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response is necessary for clearance [102]. Similar responses have been shown
in experiments utilizing the parasite Nippostrongylus brasiliensis, suggesting that
IL4 and the IL4rα chain play an important role in the ability of the body to
generate a robust Th2 response [101]. The role of IL4rα signaling has not been
studied in the response to infection with extracellular bacteria.
B. Methods
Isolation and ex vivo stimulation of splenocytes from IL4rαKO mice
Mice were humanely sacrificed and spleens were collected in RPMI + 5%
fetal calf serum (FCS) (Invitrogen, San Diego, CA). Spleens were homogenized
by pushing them through a mesh screen. Following homogenization, red blood
cells were lysed with a hypotonic lysis buffer consisting of 0.15M ammonium
chloride, 10mM potassium bicarbonate, and 0.1mM EDTA (ACK). Cells were
then washed twice with PBS and enumerated. Cells were allowed to adhere on
T75 flasks overnight in RPMI + 5% FCS. The next morning, the media was
discarded, and adherent cells were washed with PBS and scraped to enrich the
population to primarily consist of macrophages.
Cells were cultured in 24 well plates at a concentration of 4x10 5 cells per
well in 2ml of RPMI + 5% FCS. Cells were then treated with IFNγ (20ng/ml), IL4
(10ng/ml), IL13 (10ng/ml), both IL4 and IL13, or both IFN and AZM (60μM)
overnight at 37°C with 5% CO2. The next morning 50ng/ml of LPS was added to
each well. Cells were then cultured for 6 hours. Cells were scraped, washed
with PBS, and lysed in RIPA buffer consisting of 50mM Tris-HCl, 150mM NaCl,
1% (v/v) triton X-100, 1% (w/v) sodium deoxycholate, 0.1% sodium dodecyl
sulfate, and 4mM EDTA (Sigma Aldrich, St. Louis, MO). Protein concentrations
were quantified utilizing the Pierce BCA reaction kit (Rockford, IL).
Stimulation of a macrophage cell line with cytokines
The mouse macrophage cell line J774A.1 (ATCC, Manassas, VA) was
utilized for our cell culture experiments. Cells were plated in 6 well plates at a
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concentration of 2.5x106 cells/5 ml of RPMI + 5% FCS. Wells were treated with
20ng/ml IFN, 10ng/ml each of IL4 and IL13, or both 20ng/ml IFN and 60μM AZM
to receive a robust polarization to the M2 phenotype. Some wells were
additionally treated with the IKKβ inhibitor IKK-16 (Tocris Bioscience, St. Louis,
MO). IKK-16 is a kinase inhibitor that prevents the phosphorylation and
activation of IKKβ [104]. IKK-16 has also been shown to decrease TNF-α
dependent upregulation of adhesion molecules, and to decrease LPS dependent
TNF-α release in mice, showing that it exerts a significant effect on IKKβ
signaling [104]. Cells were then incubated overnight at 37°C with 5% CO2. The
next morning 50ng/ml LPS was added to all wells, and the cells were incubated
for 24 hours. Cells were scraped, washed with PBS, enumerated, and lysed in
0.1% (v/v) triton X-100. Protein concentrations were quantified utilizing the
Pierce BCA reaction kit. An aliquot of the media supernatant was collected and
frozen at -80°C for additional analysis.
Quantification of arginase activity
Arginase activity was assessed via the protocols first described by
Corraliza et. al., and is reported here as a surrogate measurement to the amount
of arginase present [92]. For detailed methods please refer to chapter two. In
brief, samples were incubated with arginine, the reaction was terminated, and a
detection reagent was added to the samples. One unit of arginase activity is
responsible for the catalysis of 1 μmole of L-arginine to ornithine and urea at a
pH of 9.5 at 37°C.
Quantification of Nitrite Concentration
Nitrite concentrations in cell culture supernatants were additionally
obtained for some experiments. When produced from NOS2, nitric oxide (NO) is
quickly degraded into nitrite and nitrate at roughly equivalent rates. These NO
breakdown products are then relatively stable in the supernatants. Nitrite
concentrations were obtained via the griess reaction [105]. In brief, a solution of
1% sulfanilamide in 5% phosphoric acid was mixed with a solution of 0.1% N-(158

napthyl)-ethylenediamine dihydrochloride. The resulting solution was then mixed
with an equivalent volume of cell culture supernatant. The samples were run in
triplicate on a microplate reader at 490nM. Absorbance was compared to a
standard curve of known nitrite concentration.
Preparation of P. aeruginosa impregnated agarose beads and mouse
infection
To ensure a viable infection, P. aeruginosa of the biofilm producing strain
M57-15 was impregnated in agarose beads. Bead preparation was an
adaptation of previously described methods [93, 94]. In the absence of agarose
beads, mice are able to quickly clear infections with P. aeruginosa. Impregnation
in agarose beads allows for a more chronic, stable infection, and leads to greater
cellular infiltration and weight loss in these animals [94]. In brief, P. aeruginosa
was first grown to late log or early stationary phase in TSB. The organism was
then added to a 2% agarose solution in PBS. This solution was then combined
with warm mineral oil, and quickly cooled. The beads were then washed twice in
solutions of deoxycholic acid to remove the mineral oil, followed by 6 washes
with PBS. Beads were resuspended in PBS, and an aliquot was collected,
homogenized, and plated on TSB agar plates to determine the number of viable
bacteria in the beads.

Considerable variability exists with the beads between

infections, resulting in variability between infections.
Dosing and Infection of IL4rαKO mice
Azithromycin tablets (Pliva, Zagreb, Croatia) were triturated and
suspended in 2% methylcellulose. Six to eight week old mice were housed in the
DLAR facility at the Biopharmacy Building at the University of Kentucky under
pathogen free conditions. The treatment group received 3.2mg (approximately
160mg/kg) of AZM daily via oral gavage, while the control group received only
methylcellulose. This AZM dose is high in comparison to the doses of AZM that
are used in humans, where doses in the range of 3-4 mg/kg/day are commonly
utilized in these patients. This was done in order to increase the likelihood that
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macrophages would be polarized to the M2 phenotype in these mice.
Preliminary experiments in vitro have shown that this dose will shift the response
toward an M2-like dominant phenotype in the lungs of these mice [63]. Thus, at
this dose we were confident that intracellular concentrations of the drug would be
adequate. Mice have metabolism rates that are many fold higher than found in
humans, producing difficulties in interspecies scaling of drug dosing in such
studies [106, 107]. AZM is primarily found intracellularly due to its partitioning
characteristics, with extremely low serum concentrations [108], therefore
equating serum concentrations in mice to those found in humans would mean
little. Because this weakens our ability to extrapolate these results to predict
clinical relevance, the importance of our translational studies (Chapter 4) is
heightened. As an antibiotic, AZM functions by binding to the ribosome of
bacteria, preventing bacterial synthesis. It is conceivable that AZM exerts
beneficial effects in subjects with CF by altering protein synthesis of molecules
involved in the degradation of IKKβ, or other molecules.
Mice were sedated and infected intratracheally with 100μl of PBS
containing P. aeruginosa agarose beads. The goal was to target the mice with
an infection of 2x105 bacteria. Because of variability inherent in our preparation
methods, and because we do not know the actual inoculum of the bead
preparation until the day after infection, in these experiments mice received
between 1.6x105 and 1.2x106 CFU of bacteria. After infection, mice were
transferred to a BSL 2 room. Mice were weighed daily, and humanely sacrificed
at various post-infection timepoints. Lung lavages were performed and first
washes were collected. Subsequently, lungs were collected and the left lower
lobe of the lung was fixed in formalin for later sectioning on a Shandon cryotome
(Thermo Scientific, Waltham, MA). The remainder of the lung tissue was placed
in RPMI + 5% FCS for additional processing. This study and all procedures were
approved by IACUC.
Adoptive Transfer
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Adoptive transfer methodologies were utilized to develop genetic
chimeras. The number of cells and timing of transfer were chosen based upon
preliminary experiments and data from others showing the ability of adoptively
transferred monocytes to abrogate inflammation-mediated pathology [51]. Bone
marrow-derived monocytes and T cells from spleens of mice were purified using
antibody cocktails with magnetic bead technologies (StemCell Technologies).
Mice were anesthetized, and 1x106 T cells and/or 1x106 monocytes were infected
retro-orbitally 1 day prior to being infected with P. aeruginosa.
Immunohistochemistry of mouse lung
After harvest, the left lower lobe of the mouse lung was placed in formalin
for at least two hours, then transferred to a 20% sucrose solution for
cryopreservation. Samples were then embedded in Tissue-Tek O.C.T.
compound (Sakura Finetek, Torrance, CA), and frozen at -80°C. Embedded
samples were then sectioned at 10μm on a Cryotome (Thermo Scientific,
Waltham, MA), and stored at -20°C until staining.
The O.C.T. compound was washed off of the sections with PBS with 0.2%
Triton X-100 (PB-X). Slides were blocked utilizing using a blocking buffer
consisting of 5% normal goat serum and 5% bovine serum albumin in PB-X
overnight at 4°C. Slides were incubated first with an antibody for arginase-1,
followed by three washes with PB-X. A FITC labeled goat anti-rabbit antibody
was then added and incubated for 1 hour at room temperature. The process was
then repeated utilizing an antibody for NOS2, and a Texas red labeled secondary
antibody.
Tissue Processing and Cell Phenotyping
Lungs were collected and processed for flow cytometry in the same
manner as in chapter 2. Three different flow cytometry panels were assessed for
each type of mouse. The first panel for the IL4rαKO mice consisted of CD11bPECy5 (Serotec, Raleigh, NC), a marker found on macrophages, GR1-PECy7, a
marker of neutrophils, MR-PE, a marker of M2 macrophages (Serotec, Raleigh,
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NC), CD80-FITC, a marker of M1 macrophages, and biotinylated I-A[d] MHC II, a
protein that is increased in expression with classical macrophage activation.
Panel 2 consisted of CD11b-APC, CD11c-PECy7 (BD Bioscience, San Jose,
CA), a marker of resident macrophages and dendritic cells, CD4-PECy5, a
marker of CD4+ T-cells, GR1-FITC, and CD19-PE, a marker of B-cells. Panel 3
consisted of CD11b-PEcy5, CD11c-PECy7, TNFα-FITC, biotinylated TGFβ, and
IL10-PE. Secondary staining was performed when appropriate utilizing a
streptavadin conjugated to APC. All antibodies were purchased from BD
bioscience (San Jose, CA), unless otherwise stated. Cells were analyzed with
utilizing a FACSCaliber Flow Cytometer (BD Biosciences, San Jose, CA) with a
dedicated operator. Greater than 50 thousand events per sample were routinely
examined. Flow cytometry analysis was performed utilizing FlowJo (Treestar,
Ashland, OR).
Statistical Analysis
Statistical analysis was performed utilizing Graphpad Prism (GraphPad
software, La Jolla, CA). Comparisons between groups were made via one way
ANOVA with Tukey’s multiple comparison test for ratio level data, and by Fisher’s
Exact test for nominal data. A repeated measures ANOVA with Tukey’s multiple
comparison test were utilized for time courses. For some data, T-tests were
used to compare means between groups. Non-linear regression utilized the least
squares method for fit. Differences in survival were assessed utilizing a log-rank
(Mantel-Cox) test. Unless otherwise stated, significance was deemed to be a p
value <0.05.
C. Results and discussion
1. Alteration of macrophage polarization with azithromycin is IKKβ
dependent
Azithromycin decreases NF-κB activation, while increasing IKKβ activation
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We first assessed select proteins in the NF-κB signaling cascade to
determine the effect that the presence of AZM has upon their activation (Figure
3.1). We treated cells with IFN, AZM, and LPS, and collected cell lysates at
various timepoints. We found that treatment with AZM resulted in increased
levels of the inactive isoform of NF-κB (p105), and decreased levels of the active
isoform (p50) NF-κB present in the cells, particularly between 5 and 30 minutes
after the addition of LPS. Congruent with these results, IκB expression was
increased by AZM. LPS causes IκB activation to decrease, as IκB binds to NFκB, keeping it inactive and preventing it from entering the nucleus to promote
inflammatory gene expression. Treatment with the drug caused IκB to reappear
earlier in the cell lysates (15 minutes after stimulation), whereas IκB was not
detected in the control samples until the 60 minute mark. However, we
additionally discovered that AZM treatment resulted in increased levels of IKKβ
present in the cells. This was surprising, because increased activation of IKKβ
should result in an increased NF-κB activation, which was not the case. The
bottom portion of Figure 3.1 shows the effect of increasing AZM concentration
upon IKKβ activation at 10 minutes after the addition of LPS (the point in time at
which there is the most difference in NF-κB activation affected by the drug).
IKKβ is dramatically increased at this timepoint at the 5, 10, and 15μM
concentrations of AZM as compared to the zero drug lane. These results
suggest that the inhibition of NF-κB activation by AZM occurs in the pathway
downstream of IKKβ (discussed below). This data provided us with evidence
suggesting that AZM polarizes macrophages to the M2 phenotype in part via
crosstalk between IKKβ and the STAT1 signaling [68].
Inhibition of IKKβ activation prevents azithromycin from polarizing
macrophages to the M2 phenotype
We then set out to determine whether AZM exerts its effect in part via the
activation of IKKβ. Fong et. al. have previously shown that activation of IKKβ
prevented polarization to the classically activated phenotype [68]. Using a
genetically engineered mouse strain that caused tissue-specific over-expression
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of IKKβ, this group showed that over-expression of the protein caused an
inhibition of M1 macrophage activation along with a blunting of inflammation
associated with Streptococcal pneumonia [68]. We treated cells with cytokines
and AZM to polarize to either the M1 or M2 phenotype, as well as with 100 nM
IKK-16, a competitive inhibitor of IKKβ (Figure 3.2). The compound displays the
high affinity for IKKβ, with an IC50 of 40nM. At higher concentrations, it can also
inhibit the activation of the entire IKK complex as well [104]. We found that
treatment with IKK-16 had no effect on arginase activity in cells treated with
IL4/13 plus LPS (the M2 control condition). In cells incubated with AZM,
however, treatment with IKK-16 decreased arginase activity to similar levels of
cells that were not exposed to the drug. This suggests that inhibition of IKKβ
prevents AZM from polarizing macrophages to the alternatively activated
phenotype, and strongly supports the conclusion that AZM shifts the macrophage
polarization balance through its effects on IKKβ.
We then assessed gene expression for arginase I in cells that were
treated with IKK-16. Cells were stimulated similarly to in the previous
experiment, except that a concentration of 50nM IKK-16 was utilized to allow the
potential for AZM to overcome this inhibition. We found that in the presence of
the inhibitor, gene expression for ARG1 was significantly decreased in cells that
were treated with AZM (Figure 3.3) (P<0.05). Interestingly, there was a trend
towards a decrease in ARG1 gene expression for wells treated with IL4/13 and
IKK-16, when compared to just the IL4/13 group (p=0.115). This data further
suggests that AZM’s ability to induce expression of ARG1, an important gene in
M2 activation, is dependent on its ability to activate IKKβ.
Finally, we assessed whether increasing inhibition of IKKβ prevented AZM
increases in arginase production (Figure 3.4). We treated cells either with IFNγ,
60μM AZM and LPS, or IL4/13 and LPS. Cells were additionally exposed to
increasing concentrations of IKK-16, to further assess the effect of IKKβ inhibition
on AZM-dependent M2 activation. We found, as expected, that inhibition of IKKβ
had little effect on IL4/13 dependent arginase production. Up to the highest
64

concentration studied, 200nM, IKK-16 did not significantly lower arginase activity.
Interestingly, however, we found that in AZM treated cells, inhibition of IKKβ by
IKK-16 greatly inhibited arginase activity in a concentration-dependent manner.
This further suggests that AZM alters macrophage polarization via IKKβ
dependent mechanisms.
Increasing azithromycin concentrations overwhelms IKKβ inhibition
We next examined the effect of AZM concentration in the presence of
IKKβ inhibition on the shift of cells to the M2 phenotype (Figure 3.5). As
expected, we found that in cells that were not treated with IKK-16, AZM treatment
resulted in a dose-dependent effect on arginase activity. When we treated cells
with 12.5nM IKK-16, we found that AZM was still able to increase arginase
activity in the cells. We did observe, however, that treatment with IKK-16 shifted
the dose-response curve to the right, showing that the inhibition caused by IKKβ
can be overcome by increasing concentrations of AZM. Increases in arginase
activity by AZM were completely ablated in the presence of with the 25nM IKK16. Unfortunately, we were not able to treat cells with AZM concentrations higher
than those we utilized due to toxicity to the J774 cells. This data suggests that
AZM achieves its effect on macrophage polarization, at least in part, via
activation of IKKβ and further pinpoints the molecular target of the antiinflammatory effects of AZM. Due to toxicity associated with very high
concentrations of AZM, we were not able to reach the plateau at which AZM
maximally increases arginase activity with these cells, and were thus unable to
fully determine the EC50.
We then assessed changes in nitrite concentration with increasing
concentrations of AZM (Figure 3.6). Nitrite concentrations in cell supernatants
serve as a counterpoint to arginase activity in cells. Nitrite is a stable breakdown
product of NO, and high levels of nitrite in cell supernatants suggest a net M1
polarization. We anticipated that AZM would be unable to decrease nitrite
concentration in cells treated with IKK-16. In the absence of IKKβ inhibition,
treatment with AZM resulted in decreased supernatant nitrite concentrations.
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Surprisingly, however, we found that we still observed decreases in nitrite
concentrations as we increased AZM concentration with our cells that were
treated with IKK-16. While it was somewhat surprising that we did not observe
an increase in nitrite concentrations with IKKβ inhibition, corresponding to a
decrease in arginase activity that we observed, these findings can still be
explained. IKKβ, as previously stated, plays an important role in multiple
signaling cascades. Inhibiting IKKβ activation results in decreased NF-κB
activation. This results in decreased activation of the M1 phenotype, and
explains why we did not see increases in nitrite concentration in our cells treated
with IKK-16. This underscores the complexity present in cell signaling. It also
suggests that the effects reported by other groups on cytokine production could
also be independent of the drug’s impact on macrophage polarization. Indeed,
IKKβ appears to be exerting two roles in macrophages, both a pro-inflammatory
role via activation of NF-κB activation, and an immunoregulatory role via STAT1
inhibition. This signaling protein may be affecting a balance function in order to
control inflammation in this setting: as classical macrophage activation occurs
along with inflammation, the NF-κB pathway could then participate in the
regulation of STAT1 signaling over time.
In summary, the changes in arginase activity that we observed by shifting
AZM and IKK-16 concentrations suggests that AZM exerts its effects on
macrophage polarization via IKKβ dependent mechanisms. A greater
understanding of these interactions and the cellular targets of AZM may lead to
future drug targets that would allow clinicians to alter inflammation without the
need to place patients on antibiotics for an extended amount of time, which leads
to increases in antimicrobial resistance.
2. Azithromycin polarizes macrophages to the M2 phenotype independent
of IL4rα function
IL4rαKO mouse splenocytes can be polarized to the M2 phenotype with
azithromycin
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We then set out to determine whether AZM’s ability to polarize
macrophages to the M2 phenotype is dependent on IL4/IL13 signaling. While we
have been able to show that AZM dependent M2 polarization requires IKKβ, we
were curious to determine if the drug signals through the IL4r and IL13r [2, 3].
First, we conducted a series of ex vivo experiments for which we collected
splenocytes from both Balb/C and IL4rαKO mice and exposed them to LPS,
cytokines, and AZM in a similar manner as described above. Figure 3.7 shows
arginase activity normalized to viable cell count for cells stimulated with LPS for 6
hours. We found that cells from KO animals treated with IFNγ plus LPS plus
AZM displayed increased arginase activity compared to all of the other conditions
that we tested. However, arginase concentrations were significantly lower than
those produced in the WT cells. This suggests that AZM may be functioning in
part by priming macrophage polarization to the M2 phenotype, at which point
cytokines produced by these cells then shift more macrophages to the M2
phenotype. As expected, IL4, IL13, or both cytokines together had little effect on
arginase production in the KO cells. The up-regulation in arginase activity that
was induced via AZM treatment in cells that are otherwise unable to be polarized
to the M2 phenotype suggests that AZM exerts its effect via IL4 and IL13
independent mechanisms.
IL4rαKO mice are more susceptible to infection with P. aeruginosa than
their parent strain
We were additionally interested to determine how mice with a deficient
ability to generate alternatively activated macrophages were able to respond to
infections with bacterial pathogens. We utilized the IL4rαKO in part to answer
this question. In addition to the IL4rαKO mice, we utilized 2 other strains of mice
to help to assess this question, the Balb/c and C57bl/6 strains. The Balb/C and
C57bl/6 strains have extremely different cytokine profiles during infections, and
resultingly respond to these infections very differently. C57bl/6 mice display high
levels of IFNγ and low levels of IL4. Their macrophages additionally express
high levels of iNOS, and low levels of the enzyme arginase [46]. Balb/c mice,
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however, have more of a Th2-dominant response. They in general produce high
levels of IL4, low levels of IFNγ, and express lower levels of the protein iNOS as
well as high levels of the enzyme arginase 1 [46]. Interestingly, when mice are
infected intratracheally with bacteria, the Th2 polarization present in the Balb/c
strain of mice is traditionally associated with better outcomes to the infection [46],
with the mice being more likely to survive. In fact, lung damage and fibrosis are
readily induced by infection with P. aeruginosa in C57Bl/6 mice, but BALB/c mice
are immune to this pathology [109-111].
Because of the differences in response of the inbred strains, we infected
C57bl/6, Balb/c and IL4rαKO intranasally with P. aeruginosa at various
inoculums, and assessed survival (Figure 3.8). Intranasal inoculations were
utilized primarily to ensure a potent acute infection. As we expected, C57bl/6
mice were susceptible to infection with P. aeruginosa, while Balb/c mice were
resistant, as it took an extremely high inoculum of 1010 CFU to cause appreciable
mortality. Interestingly, however, while their parent strain is resistant to
intranasal infection with P. aeruginosa, the IL4rαKO strain was much more
susceptible to infection with P. aeruginosa. Indeed, the survival curve for the
IL4rαKO mice more closely resembles the C57bl/6 strain than the Balb/c strain,
suggesting that alternative macrophage activation through IL4rα may be partly
responsible for the innocuous inflammatory response observed in the Balb/c
strain.
We next examined histology for the three different strains of mice, and
found marked differences. Balb/c mice showed diffuse cellular infiltrations
throughout the lungs (Figure 3.9 A.). The cellular infiltrates in C57bl/6 were
primarily concentrated along the edges of small airways (Figure 3.9 B.). The
lungs of the IL4rαKO mice displayed cellular infiltrates that, while somewhat
diffuse, were more concentrated along the airways than those of their parent
strain (Figure 3.9 C.). This finding could have clinical relevance, due to the fact
that P. aeruginosa infection in patients with CF primarily causes a peribronchiolar
inflammation and damage. This again shows that the IL4rαKO mice more closely
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resemble the P. aeruginosa susceptible C57bl/6 strain, and suggests that
alternatively activated macrophages play an important role in the ability of mice
to blunt the damaging inflammatory response associated with P. aeruginosa
infection.
We additionally examined differences in surface protein expression and
cytokine production in IL4rα KO mice. Mice were sacrificed 6 days after infection
with between 3.8 x 104-3 x 105 CFU of P. aeruginosa incorporated into agarose
bead, and lung digest samples underwent surface staining as well as intracellular
cytokine staining, and analyzed by flow cytometry. We first assessed the
expression of surface markers of macrophages (CD11b), T cells (CD4), and
neutrophils (approximated by GR-1 expression) (Figure 3.10 A.) and compared
the results to the WT strain. While we did not observe significant differences, we
found trends that IL4rαKO mice displayed fewer CD4+ T cells (p=0.203), and
more GR1+ cells (p=0.110). We then assessed expression of surface markers of
macrophage polarization and compared the results between the two strains
(Figure 3.10 B.). Encouragingly, we found that IL4rαKO mice displayed
significantly fewer cells expressing the M2 markers MR (p=0.047) and CD23
(p=0.043), while observing no differences in surface expression of the M1 marker
CCR7 between the strains. Finally, we assessed intracellular expression of proand anti-inflammatory cytokines including TNFα, TGFβ and IL10 (Figure 3.10 C.).
We found a trend towards a decrease in the number of cells producing TNFα
(p=0.109). We additionally found no differences in the numbers of cells
expressing the anti-inflammatory cytokines TGFβ and IL10, although there was a
trend towards a significant difference in the latter (p=0.063). These phenotypic
differences suggest the importance of control of macrophage activation via the
IL4 and IL13 receptors, and the role of these macrophages in the response to P.
aeruginosa infections.
To this point, we have described how the absence of IL4rα function results
in impaired survival and increased inflammation in mice infected with P.
aeruginosa. This suggests that M2 macrophages play an important role in the
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response to P. aeruginosa in the lungs of these mice. We believe that the lack of
M2 macrophage polarization results in an overly zealous inflammatory response
that causes excessive damage, thereby increasing morbidity and mortality.
IL4rαKO mice adoptively transferred with cells from Balb/c mice display
IL4rα+ cells in their lungs
A confounding factor in using this genetically engineered strain of mouse
is that not only are macrophages devoid of IL4rα—this defect is also present
among T lymphocytes. Therefore, to address this issue, we utilized an adoptive
transfer approach to restore normal IL4rα expression in these cell types. We set
out to compare the response to P. aeruginosa pneumonia among IL4rαKO mice
that received adoptive transfer of either normal T cells only, or both normal T
cells and monocytes. In order to validate the transfer of cells, we first confirmed
that WT cells adoptively transferred into IL4rαKO mice would migrate to the lungs
in response to infection. On the day before infection, IL4rαKO mice were
adoptively transferred with both monocytes and T cells, or with only T cells from
Balb/c mice, as described above. The IL4rαKO mice have deficient IL4rα KO
function on all of their cells, including T cells. Mice were then infected
intratracheally with P. aeruginosa-incorporated agarose beads, and sacrificed at
various time points. Cells were collected and stained for CD11b, GR1, CD4, and
IL4rα. We first assessed the presence of the IL4rα chain on macrophages,
defined as cells being CD11b+ as well as GR1-. As expected, we found
macrophages expressing the IL4rα chain in mice that received both
macrophages and T cells, whereas IL4rα expression was absent in the group
receiving normal T cells only (Figure 3.11). Interestingly, we first began to see
this difference at 7 days post infection. This resembles our previous studies in
C57bl/6 mice, showing that the influx of cells into the lungs of mice is most
pronounced at 7 days post infection. When we assessed the presence of the
IL4rα chain on T cells that had been adoptively transferred, we found significant
amounts of T cells that expressed the ILr4α chain in both of the groups. This
data shows that we are able to effectively adoptively transfer cells with normal
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IL4rα chain function to mice lacking the IL4rα chain. This allows us to assess the
importance of IL4rα chain signaling specifically associated with macrophages in
the context of pulmonary infections with P. aeruginosa.
Impact of Adoptive Transfer on Weight Loss and Survival
We assessed survival and weight loss in our IL4rαKO mice that had been
adoptively transferred with cells from Balb/c mice. We pooled survival data from
3 replicate experiments to determine whether there was a difference between the
groups. We first found that there was no difference in survival between animals
that received both macrophages and T cells, as compared to animals that only
received T cells (p=0.0939) (Figure 3.12 A.). We also found no differences in
weight loss between the two groups at any specific timepoint, or in total over time
(p=0.3147) (Figure 3.12 B.). It is important to note, however, that we observed
few fatalities in these experiments. This may be due to the initial inoculula that
we utilized being too low for the mice. Additionally, with the addition of normal T
cells to these mice, these cells may allow for better control of the inflammatory
response.
Effect of adoptive transfer on cellular influx into lungs of IL4rα KO mice
We next examined the cellular infiltrates of infected IL4rαKO mice that
underwent adoptive transfer of either WT macrophages and T cells or only T
cells (Figure 3.13). We observed a decrease in the numbers of infiltrating
macrophages on day 7 post-infection (p=0.04) (CD11b+CD11c-GR1-) in mice
that received both M and T cells, compared to mice that received only T cells.
We did not, however, observe any differences in the amounts of the more
alveolar subset of cells in the lungs, designated as CD11b-CD11c+GR1-.
Importantly, mice that only received T cells and monocytes displayed
dramatically greater neutrophil influx (as approximated by the number of GR1+
cells) in the lungs than mice that received T cells, peaking around day 7 postinfection. This suggests that M2 macrophages play an important role in
decreasing the neutrophilic response in acute infections with P aeruginosa
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pneumonia. This is an important finding, as dysregulated inflammation
characteristic of patients with CF is primarily neutrophil driven, as presented in
detail in Chapter 1. We also observed a decrease in CD4+ T cells in mice that
received macrophages capable of M2 polarization. Although adoptive transfer
changed the influx of immune cells over time in the lungs, in general it did not
bring the values to the levels observed in the WT strain.
Ability of azithromycin to rescue mice infected with P. aeruginosa that lack
IL4rα responses
We demonstrated in Chapter 2 that AZM can blunt inflammation and
improve lung damage and survival in C57Bl/6 mice infected with P. aeruginosa.
Data presented in this chapter suggests that the converse is also true: that the
absence of alternative macrophage activation (i.e. absence of IL4rα signaling)
worsens neutrophil-driven pulmonary inflammation associated with this infection.
To apply these results to our mechanistic investigation of the drug, we next
assessed the ability of AZM to induce alternative macrophage activation in
IL4rαKO mice, and whether this will blunt the excessive inflammation associated
with P. aeruginosa infection in this strain. IL4rαKO mice were infected with
agarose beads containing between 5.5 x 104 and 1.5 x 105 P. aeruginosa for
these experiments. Beginning 4 days before infection mice were dosed with
3.2mg AZM per day, and mice sacrificed at various timepoints for analysis.
We first assessed the numbers of bacteria present in the lungs of KO mice
that had been infected with P. aeruginosa beads. In the past, we have observed
that treatment with AZM exerted no effects on bacterial colony counts in Balb/c
mice that had been infected with P.aeruginosa [75]. Here, we found similar
results. We found no differences in bacterial CFU at any of the three timepoints
that we collected (Figure 3.14). We then assessed the percentage of weight loss
from day 0 in our KO animals (Figure 3.15). Here we found no differences in
weight loss between the KO animals that received AZM as animals that did not
receive AZM (p=0.0649 by 2-way ANOVA). These findings mimic those that we
observed with our adoptive transfer.
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Azithromycin shifts cells in the lung to the M2 phenotype in IL4rαKO mice
We next assessed the phenotype of cells in both the lung lavage and lung
digests of the IL4rαKO mice infected with P. aeruginosa for markers of M1 and
M2 activation via flow cytometry. We found a non-significant trend towards
increased expression of the M2 marker mannose receptor on cells in the lung
lavages of mice treated with AZM (Figure 3.16 A.). We additionally observed
trends towards increased MR expression in the percentages of cells in the lung
lavage of the mice, which became statistically significant at day 14 (p<0.05)
(Figure 3.16 C.). Intriguingly, we did not observe differences in mannose
receptor expression in the lung digests, both when assessing the total number of
cells positive for both CD11b and MR, as well as when we compared the
percentages of cells in the digest that were CD11b+ that also expressed MR
(Figure 3.16 B., D.). It is possible that the large amount bacterial antigen in the
lungs of these mice was able to overwhelm the ability of AZM to alter
macrophage to the M2 phenotype.
We next assessed surface expression of CD80, a marker of M1 activation.
Here we found few differences between the two groups, and in fact observed a
slight increase in both the number and percent of cells expression CD11b that
also expressed CD80 (Figure 3.17 A., C.). Again, we observed no differences
between the two groups in the lung digest (Figure 3.17 B., D.). It is important to
note, however, the very large percentages of cells, especially in the lung lavage,
that were positive for CD80 across all of the time points. This again suggests
that in IL4rαKO animals there is strong inflammatory response to bacteria. In a
mouse with normal IL4rα function we would expect this inflammatory response to
be dampened by M2 macrophages that were activated via traditional
mechanisms. In the IL4rαKO mice, however, there may be less of a shift away
from an M1 macrophage polarization, even in the presence of AZM. Again, this
could be a matter that the large amount of bacterial signaling that is present in
the lungs of these mice is overwhelming the ability of AZM to help achieve a shift
to the M2 phenotype.
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We then plotted the ratio of cells that had CD80 surface expression to that
of cells that had MR surface expression, the results of which can be seen in
figure 3.18. In the lung lavage we observed that the ratio of cells that expressed
either CD80 or MR at day 0, 4, and 7 (Figure 3.18 A.). Interestingly, however, at
day 14 we observed an increase in the ratio of CD80 positive cells to MR+ cells.
This increase was significantly higher in mice that did not receive AZM as
compared to mice that received AZM. By day 14, mice had essentially cleared
the bacteria, and were in the process of recovering from the infection. It is only
after the infection had been cleared that we are able to observe significant
differences in the CD80/MR ratio, suggesting that AZM is able to shift
macrophage polarization in these mice towards the M2 phenotype. We observed
similar findings in the lung digest (Figure 3.18 B.), although rather than observing
essentially no changes in the ratio across days 0, 4, and 7, we saw a trend
towards a gradual, non-significant increase in the ratio of CD80/MR positive cells.
Again, we observed that at day 14 a significantly higher CD80/MR ratio in mice
that did not receive AZM when compared to mice that did receive AZM.
Azithromycin alters influx of inflammatory cell types in IL4rαKO mice
We then assessed the ability of AZM to alter cellular influx to the lungs of
mice during infection with P. aeruginosa. We have previously shown that in
C57bl/6 mice treatment with AZM increases the influx of CD11b+ cells, and
decreases the influx of neutrophils in the lungs [75]. Here we observed similar
findings in our KO animals. In the lung digests, we found a significant increase in
the ratio of CD11b+ cells (representing infiltrating macrophages) to neutrophils
(CD11b- GR1+) at day 7 in the lung digest (Figure 3.19 B.). Unfortunately, the
large variability in the lung lavage data on day 7 made it impossible to observe
any differences in cell influx (Figure 3.19. A.). The large difference at day 7 in
the lung digest, however, suggests that AZM is altering the types of cells that
influx into the lungs of mice during an acute infection with P. aeruginosa
independent of IL4 and IL13 dependent mechanisms.
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We also examined lung histology from the mice at various timepoints, to
visually assess the types of cells that infiltrate into the lungs (Figure 3.20). On
day 0, we found few cells in the lungs, and the cells that we did see were
mononuclear, and appeared to be monocytes and macrophages. On day 4 we
observed many more cells in the lungs of the mice. While in both the AZM and
non-AZM treated animals we observed more neutrophils (as determined by the
appearance of the nuclei of the cells), it appears that there were fewer
neutrophils in the mice treated with AZM than in the animals that did not receive
AZM. On day 7, we observed similar trends, although the differences between
the AZM treated animals and the animals that did not receive AZM was not very
large. By day 14 the infection is essentially resolved, and we observed many
fewer cells in the lungs of the animals at this point in time. We also did not
observe major differences in the types of cells present in the lungs of the animals
at this timepoint.
Azithromycin treated IL4rαKO mice display shifts in arginase 1 and NOS2
localization
We additionally assessed the localization of two of the prototypical
proteins of macrophage polarization, NOS2 for M1 macrophages, and arginase 1
for M2 macrophages. While we did not observe large differences in total
arginase activity in our IL4rαKO mice that we treated with AZM (Figure 3.21), we
found profound differences in the relative location of arginase in the lungs of
these animals when employing IHC. On day 14 post-infection with 1.5 x 105 CFU
of P. aeruginosa incorporated into agarose beads, we found that animals that
had not received AZM displayed expression of both NOS2 and arginase 1
(Figure 3.22). Animals that did receive AZM, however, expressed markedly less
NOS2 protein. Interestingly, we found a marked up-regulation of arginase 1
protein in the animals treated with AZM. This increase was most pronounced in
the areas around the small airways of these mice, as compared to the rest of
their lungs. This is the typical location of P. aeruginosa infection, and is
additionally the area affected most severely in CF pathogenesis. This suggests
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that AZM is able to polarize macrophages away from the M1 phenotype (as
determined via NOS2 protein expression). It also appears that AZM treatment is
increasing M2 polarization in the lungs of these animals, to a certain extent in the
entire lung, but to a greater extent around the airways. This suggests that AZM,
in addition to the effects that it exerts on macrophage polarization, is affecting
trafficking of macrophages in the lungs of these animals. In fact, it appears that
AZM is causing M2 macrophages to concentrate in the peribronchiolar areas
around the airways.
It is unknown what the impact of this effect may be. First, it is possible
that these M2 macrophages would result in increased fibrosis and scarring in the
airways around the lung. Second, the marked decrease in NOS2 protein
expression in mice treated with AZM suggests that there may likely be less total
damage in the lungs of these animals to recover from. In that case, it may be
that even though we found markers consistent with M2 macrophages around the
airways of these mice, airway damage may not necessitate repair and
remodeling to a significant extent.
D. Conclusions
General Conclusions
Here we have shown data suggesting that AZM polarizes macrophages to
the M2 phenotype via IKKβ-dependent, and IL4rα-independent mechanisms.
Others have shown that IKKβ prevents activation of STAT1 in myeloid cells [68].
We showed that treating cells with an inhibitor of IKKβ activation prevents AZM
from polarizing macrophages to the M2 phenotype. We additionally showed that
with certain degrees of IKKβ inhibition, increasing AZM concentration was able to
overwhelm this inhibition. This suggests that AZM is somehow causing the
activation of IKKβ, and that this activation is at least in part responsible for
polarization away from the M1 phenotype, and towards the M2 phenotype for
these macrophages. We additionally showed, utilizing cells stimulated ex vivo
from IL4rαKO mice,that AZM is still able to shift macrophages to the M2
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phenotype, even in the absence of signaling via the traditional methods
necessary for M2 polarization.
This data suggests future targets for investigation into the exact molecular
site where AZM is exerting anti-inflammatory effects. Future work targeting these
molecules may allow for the creation of novel therapeutics that include the
beneficial immunomodulatory effects of AZM, without the anti-infective
properties. This would result in the avoidance of inducing antimicrobial
resistance that results from long term treatment with an antibiotic. Antibiotic
resistance is a growing problem, and it has been shown that long-term macrolide
treatment greatly increases resistance to those medications [17]. While we were
not able to find an exact target and mechanism by which AZM alters macrophage
phenotype, we were able to considerably narrow the field of targets. Namely, by
showing that inhibition of IKKβ prevents AZM based M2 polarization, it suggests
that activation IKKβ plays an important role in this activation. We hypothesize
that this is due to inhibition of the STAT1 cascade similar to what Fong et. al.
have previously shown [68]. The Fong article suggests an interaction between
the two important cell signaling mechanisms in macrophages. They surmise that
this interaction exists to down-regulate the inflammatory response in cells. We
believe that AZM polarizes macrophages to the M2 phenotype via this
mechanism.
Additionally, we were able to show that AZM dependent M2 activation is
independent of IL4 and IL13 function, suggesting that it does not depend on the
traditional mechanisms associated with M2 activation. This eliminates one
prospective mechanism for AZM dependent activation, and further supports our
previous finding that AZM shifts macrophage polarization to an M2 phenotype in
the presence M1 stimulation conditions.
We additionally showed that AZM is able to exert many of the effects in
vivo that it was able to exert in vitro, even in mice lacking IL4rα signaling. AZM
increased the number and percentages of cells in the lung lavage expressing
MR. When mice had cleared the infection on Day 14 of the experiment, we
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observed a shift towards expression of the M2 marker MR, and a shift away from
the M1 marker CD80. In the absence of an intrinsic M2 response to blunt the
initial inflammatory response to pulmonary infection with P. aeruginosa, AZM was
unable to affect a major phenotypic shift in macrophages in vivo. As the infection
begins to clear, however, and the infectious burden falls in the lungs, it appears
that AZM is able to exert a more major effect on the macrophage phenotype in
the lungs of these animals.
Limitations
It was initially difficult for us to make comparisons between the three initial
mouse strains that we utilized (C57,bl6, Balb/c, and the IL4rαKO mice). As
previously stated, the IL4rαKO mice are on a Balb/c background. The Balb/c
strain is traditionally thought to be resistant to pulmonary infection with
Pseudomonas, especially compared to the C57bl/6 strain which is susceptible to
severe acute pulmonary damage induced by Pseudomonas infection [46, 47].
This means that our KO mice are on a background for a strain that is resistant to
pulmonary infections. While this allows us to make some interesting
observations (e.g. that a defect in IL4rα signaling shifts the phenotype from a
pulmonary infection resistant strain to a pulmonary infection susceptible strain), it
does make comparisons between groups difficult. Namely, it is difficult to
compare these mice to their parent strain, since a bacterial inoculum that would
kill an IL4rαKO or C57bl/6 mouse is easily cleared by a Balb/c mouse. With that
in mind, however, we were still able to make interesting observations with the
IK4raKO mice on the background that we have them.
There is variation between the flow cytometry assessment of the types of
cells present in the lungs of these mice, and the visual inspection of the cells via
histology. Namely, we observed our largest differences in the ratio of
macrophages to neutrophils at day 7 via our flow cytometry analysis, and in our
visual analysis of the lungs the largest difference appears to have been on day 4.
It is important to note that while the lung lavage and lung digest samples
represent cells from the entire lungs of the animals, the histology sections
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represent only a thin slice of the lungs. This means that the histology results
may not be fully representative of the rest of the lungs of the animal. Regardless
of the specific day that we observed the largest difference in the macrophage to
neutrophil ratio in the lungs of these mice, the consistent trend between the two
groups is that AZM treated animals displayed a more monocytic, and less
neutrophilic influx into their lungs in the context of a bacterial pneumonia.
We additionally had considerable variation in our mouse experiments in
regards to our infections of IL4rαKO animals. The infection model that we use for
our mice is extremely complex and results in considerable variation, both
between individual mice that are infected, as well as between experiments. The
P. aeruginosa agarose beads are extremely difficult to make, and variability in
bead production makes it difficult to target the same inter-experiment dose. This
results in difficulty comparing replicates of infections. Additionally, there is
difficulty in ensuring that all mice receive the same amounts of bacteria in their
intratracheal inoculation. This may explain some of the considerable variability
that we observed with our flow cytometry and other data from our mice. Instead
of the intratracheal infection approach that our lab utilizes for the infections,
others first tracheotomize the animals for the infection [112]. That approach,
however, has considerable trauma associated with it, leading to alterations in the
immune response. We believe that these alterations make the infection
approach that we utilize to be more appropriate, as we see fewer alterations in
the immune response. Due to the nature of our infection model, and the ease in
which mice are able to clear pulmonary infections with P. aeruginosa, we are
forced to utilize this model, with all of the benefits and difficulties entailed to it.
Finally, we cannot eliminate the possibility that AZM is exerting effects on other
cells, including neutrophils T cells, and epithelial cells. These effects on other
cells may be responsible in part for the beneficial effects seen with AZM.
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Figure 3.1. Western blots of proteins in the NF-κB cascade. J774 cells were
stimulated with IFN, LPS and 30 μM AZM for variable amounts of time at 37°C
with 5% CO2. Lysates were probed for proteins in the NF-κB cascade, including
inactive NF-κB (p105), active NF-κB (p50), and IκB. Cells were then stimulated
for 10 minutes for IFN, LPS, and variable concentrations of AZM, and probed for
IKKβ. 10 minutes were utilized for IKKβ experiments due to large differences in
NF-κB activation observed in the samples.
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Figure 3.2. Arginase activity in the presence of an IKKβ inhibitor. J774 cells
were stimulated overnight with IFN, IL4/13, 30 μM AZM, and 100nM of the IKKβ
inhibitor IKK-16 at 37°C with 5% CO2. Cells were then stimulated with LPS for 24
hours. Cells were then lysed, and lysates were utilized for the arginase assay.
Statistical analysis was performed with a one way ANOVA with Tukey’s multiple
comparison test. Arginase samples were run in triplicate, and data represents
mean ± SD. Data representative of 3 replicates. Data deemed statistically
significant with P<0.05
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Figure 3.3. Arginase 1 gene expression in the presence of an IKKβ inhibitor.
J774 cells were stimulated overnight with IFN, IL4/13, 30 μM AZM, and 50 nM of
the IKKβ inhibitor IKK-16. Cells were then stimulated with LPS for 24 hours at
37°C with 5% CO2. Cells were preserved in RNAlater, mRNA was isolated, and
qRT-PCR was performed on each sample in triplicate. Statistical analysis was
performed via T-tests for related samples. Data represents mean ± SD. Data
representative of 2 replicates.
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Figure 3.4. Arginase activity with increasing concentrations of an IKKβ inhibitor.
J774 cells were stimulated overnight with IFN and 30 μM AZM or IL4/13. Cells
were also treated with increasing concentrations of IKK-16. Cells were then
stimulated with LPS for 24 hours at 37°C with 5% CO2. Cells were lysed, and
lysates were utilized for the arginase assay. Results were normalized to
conditions with no IKK-16. * represent significant decreases from baseline
assessed via ANOVA. Arginase samples were run in triplicate, and data
represents mean ± SD.
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Figure 3.5. Arginase activity with increasing concentrations of AZM. J774 cells
were stimulated overnight with IFN, IL4/13, IKK-16, and variable concentrations
of AZM. Cells were then stimulated with LPS for 24 hours at 37°C with 5% CO 2.
Arginase samples were run in triplicate, and data represents mean ± SD.
Results were normalized to conditions with no AZM. Non-linear regression of
data was fit utilizing a log(agonist) vs. three parameter response in Graphpad
Prism. Data representative of three replicates.
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Figure 3.6. Nitrite concentration with increasing concentrations of AZM. J774
cells were stimulated overnight with IFN, IL4/13, IKK-16, and variable
concentrations of AZM. Cells were then stimulated with LPS for 24 hours at
37°C with 5% CO2. Samples were run in triplicate, and data represents mean ±
SD. Non-linear regression of data was fit utilizing a log(agonist) vs. three
parameter response in Graphpad Prism. Data representative of three
replicates

85

Figure 3.7. Arginase activity in ex vivo stimulated mouse splenocytes.
Splenocytes were collected and stimulated overnight with IFN, IFN+AZM, IL4,
IL13, IL4/13, or no cytokines at 37°C with 5% CO2. Cells were then treated for 6
hours with LPS. Lysates were collected, and the arginase assay was performed
on the lysates. Each sample was run in triplicate. Statistical analysis was
performed via one way ANOVA with Dunnett’s multiple comparison test.
Samples were compared to the IFN+AZM+LPS group. Differences were deemed
significant with a p<0.05.
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Figure 3.8. Survival curves with increasing inocula of P. aeruginosa in C57bl/6,
Balb/c, and IL4rαKO mice. Mice were infected intranasally with between 10 5 and
1010 P. aeruginosa, and monitored over time.
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Figure 3.9. Lung sections from mice infected with P.aeruginosa. Lung sections
were collected, and H & E staining was performed on the lung sections.
Sections are from mice that were of the strain (A) Balb/c; (B) C57bl/6; (C) IL4rα
KO. Balb/c mice displayed diffuse cellular infiltrations throughout the lung
section, while in C57bl/6 mice cells are concentrated along the small airways.
Cellular infiltrates in the IL4rα KO mice more closely resemble the C57bl/6 mice
than those of Balb/c. Pictures representative from multiple pictures/mouse.
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Figure 3.10. Phenotype of cells collected from either Balb/c or IL4rα mice.
Lungs were collected, and lung digests were stained for flow cytometry. Panel
(A) cells positive for CD11b (macrophages), CD4 (T cells), or GR1 (neutrophils
and inflammatory monocytes); (B) The subset of CD11b positive cells positive for
MR, CCR7, CD23; (C) subset of CD11b positive cells intracellularly expressing
TNFα, TGFβ and IL10. Data represents mean number of cells expressing the
surface markers ± SD, and are from 4 mice/group.
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Figure 3.11. Adoptive transfer into IL4rα KO mice. Bone marrow derived
monocytes and T cells (M + T) from spleens, or just T cells (T) of Balb/c mice
were isolated and adoptively transferred into IL4rα KO mice on day -4 before the
experiment. On day 0, mice were intratracheally infected with agarose beads
containing 5 x 105 P. aeruginosa. Surface receptor expression in the lung
digest samples were assessed via flow cytometry. Cell counts are depicted for
the CD11b+GR1-IL4rα+ and the CD4+IL4rα+ subsets of cells. Data represents
mean ± SD for 4 mice/group.
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Figure 3.12. Survival and weight loss with adoptively transferred mice. IL4rαKO
mice were adoptively transferred with either macrophages and T cells (M + T), or
just T cells from Balb/c mice on day -4 of the experiment. On day 0, mice were
infected with agarose beads containing P. aeruginosa. Data is pooled from 3
replicates of the experiments. Panel (A) represents percent survival between the
two groups; (B) weight loss normalized to day 0. Data represents mean ± SD.
Experiment began with 16 mice/group
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Figure 3.13. Phenotype of cells in lungs of adoptively transferred mice. Cells
from Balb/c mice were adoptively transferred to IL4rαKO mice on day -1, and
infected with agarose beads containing P. aeruginosa. Balb/c animals were
utilized as a control. Cell phenotypes were assessed via flow cytometry. Panels
represent post infection lung digest cell counts for CD11b+CD11c-GR1(infiltrating macrophages), CD11b-CD11c+GR1- (resident macrophages), GR1+
(neutrophils), and CD4+ (T cells). Data represents mean ± SD with 4
mice/group.
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Figure 3.14. Bacterial CFU in IL4rαKO mice treated with AZM. Beginning four
days before infection, mice received either 3.2 mg AZM daily, or vehicle control
beginning 4 days before infection, and continuing throughout the infection. Mice
were then infected intratracheally with 5.5 x 104 bacteria, and monitored over
time. Lungs were collected, and a portion were homogenized and plated to
determine the numbers of viable P. aeruginosa. Data represents mean ± SD
with 4 mice/group.
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Figure 3.15. Weight loss in IL4rαKO mice treated with AZM. Mice were
treated with 3.2 mg AZM or vehicle control daily beginning 4 days before
infection with agarose beads containing 1.5 x 105 P. aeruginosa. Data
shown is normalized to percent weight from day 0. Data represents
mean ± SD, and is representative of two experiments.
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Figure 3.16. Counts and percentages of CD11b+MR+ cells in the lungs
of IL4rαKO mice treated with AZM . Mice were treated with AZM or
vehicle control beginning 4 days before infection with agarose beads
containing 1.5 x 105 P. aeruginosa. Cell phenotypes were assessed via
flow cytometry. Panels (A) and (B) represent the number of cells
positive for CD11b which also expressed MR in the (A) lung lavage; (B)
lung digest. Panels (C) and (D) represent the percentage of CD11b+
cells also expressing MR in the (C) lung lavage; (D) lung digest. Data
represents mean ± SD from 4 mice/group. Statistical analysis was
performed utilizing repeated measures ANOVA with Bonferroni’s post
test. Data is representative of two experiments.
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Figure 3.17. Counts and percentages of CD11b+CD80+ cells in the lungs of
IL4rαKO mice treated with AZM. Mice were treated with 3.2 mg AZM or vehicle
control beginning 4 days before infection with agarose beads containing 1.5 x
105 P. aeruginosa. Cell phenotypes were determined via flow cytometry.
Panels (A) and (B) represent the number of cells positive for CD11b which also
expressed CD80 in the (A) lung lavage; (B) lung digest. Panels (C) and (D)
represent the percentage of CD11b+ cells also expressing CD80 in the (C) lung
lavage; (D) lung digest. Data represents mean ± SD from 4 mice/group.
Statistical analysis was performed utilizing repeated measures ANOVA with
Bonferroni’s post test. Data is representative of two experiments.
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Figure 3.18. Ratio of CD80 to MR positive cells in lungs of IL4rαKO mice
treated with AZM. Mice were treated with 3.2 mg AZM or vehicle control daily
beginning 4 days before infection with agarose beads containing 1.5 x 10 5 P.
aeruginosa. The number of CD11b+ cells expressing CD80 were divided by
the number of CD11b+ cells expressing MR. Number of cells positive for
various surface markers were determined via flow cytometry. Data represents
mean ± SD from from 4 mice/group. Statistical analysis was performed
utilizing repeated measures ANOVA with Bonferroni’s post test. Assessing
differences in ratios was utilized to determine subtle differences in net
macrophage polarization.
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Figure 3.19. Ratio of CD11b+ cells to neutrophils in lungs of IL4rαKO mice.
Mice were treated with 3.2 mg AZM or vehicle control daily beginning 4 days
before infection with agarose beads containing 1.5 x 105 P. aeruginosa. The
number of CD11b+GR1- cells were divided by the number of CD11b-GR1+
cells. Number of cells positive for various surface markers were determined via
flow cytometry. Data represents mean ± SD from from 4 mice/group. Statistical
analysis was performed utilizing repeated measures ANOVA with Bonferroni’s
post test.
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Figure 3.20. Lung sections of IL4rαKO mice treated with AZM. Mice were
treated with 3.2 mg AZM daily beginning 4 days before infection with agarose
beads containing P. aeruginosa. Lung sections were stained with H & E.
Columns represent mice that did or did not receive AZM, while rows show the
various days in which sections were collected.
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Figure 3.21. Arginase activity in IL4rαKO mice treated with AZM. Mice were
treated with either 3.2 mg AZM or a vehicle control daily beginning 4 days
before infection with agarose beads containing 1.5 x 105 P. aeruginosa. Lung
digests were collected, lysed in RIPA buffer, and analyzed with the arginase
assay. Data represents mean ± SD with four mice/group, and is representative
of two experiments.
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Figure 3.22. Arginase 1 and iNOS localization in IL4rαKO mice treated with
AZM. Lung sections from mice 14 days post infection with agarose beads
containing 1.5 x 105 P. aeruginosa were stained with primary antibodies to both
arginase 1 and iNOS, with either FITC or texas red secondary staining. Panels
represent arginase 1 localization, iNOS localization, and merged data, from left
to right. Data representative of multiple pictures from one mouse/group. Other
timepoints displayed similar results (data not shown).
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Chapter 4. Correlation of macrophage-associated gene expression to
clinical characteristics in patients with cystic fibrosis
A. Introduction
Chapter overview
To conclude this work we characterized the impact of chronic AZM
therapy on macrophage gene expression and markers of inflammation in the
lungs of patients with CF, as well as the relationship between macrophage
polarization and lung function in these patients. While it has previously been
shown that AZM improves markers of clinical function in patients with CF, we
were interested in determining whether AZM alters macrophage phenotype in
patients with stable CF, to extend our earlier findings both in vitro and utilizing
our mouse infection model [16, 18, 20]. The data presented to this point was
generated in cells and animals with functional CFTR protein, a difference that
could potentially lead to difficulty in extrapolating that data to humans. To
assess the impact of AZM therapy on macrophage phenotype in patients with
CF, we collected sputum samples from patients at both the pediatric and adult
Cystic Fibrosis clinics at the Kentucky Clinic, isolated mRNA from the cells, and
correlated the gene expression to the patient’s clinical status. We were primarily
interested in assessing gene expression in patients who were stable in their
disease. This was to assess the effect of AZM on macrophage polarization
while minimizing confounding factors associated with acute infection and flare of
the disease, and the changes in gene expression and cellular influx that results.
We hypothesized that M2 macrophage polarization would be correlated to
declines in lung function in patients with CF and that AZM therapy would
additionally polarize macrophages to the M2 phenotype.
Cystic Fibrosis: a brief overview
Defects in the CFTR lead to impaired chloride reabsorption. This results
in thick, dehydrated secretions in the lungs of patients with CF [11]. These
thickened secretions provide an excellent breeding ground for a wide variety of
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bacteria, most notably P. aeruginosa [11]. It is exceptionally difficult for patients
with CF to clear the bacteria, and over time they are considered to be chronically
colonized with the organism. The course of the disease is characterized by
repeated flares of inflammation caused by acute infections, followed by repair
and recovery. The cycle then repeats, causing a vicious circle of exacerbation,
followed by a decline in lung function over time, which then makes it more likely
that the patient will have a bacterial flare in the future [113]. These changes in
lung function can be tracked in a variety of ways, most notably by assessing the
forced expiratory volume in one second (FEV1), specifically the percent of the
predicted value for the patient. FEV1 represents the volume of air that a patient
can expel from their lungs in 1 second after fully inhaling. This value can then be
compared to the expected volumes of a patient with similar age, height, and
other physical parameters [114]. FEV1% predicted is commonly used as one of
the key parameters in assessing disease progression in patients with CF. While
the lungs are the organ in which CF symptoms are the most life-threatening, it
also effects many other organ systems in patients, including the pancreas, the
digestive tracts, and the reproductive tracts [22, 23]. As one would expect from a
disease that affects multiple systems, patients with CF commonly receive large
numbers of medications to treat the associated symptoms. This results in a
significant number of potential confounding factors in any clinical study, and
makes comparisons difficult. For the purposes of this dissertation, we will be
focusing on medications that deal with the pulmonary symptoms of CF, as well
as any immunomodulatory agents that they may be taking. Previous data from
our laboratory has shown that subjects with CF displayed an inverse correlation
between parameters of lung function and markers of M2 activation [115]. We
found that the negative relationship in MR surface expression was more
pronounced in subjects who were not colonized with P. aeruginosa, as compared
to subjects who were colonized with P. aeruginosa. We also found that arginase
activity was inversely correlated with lung function in subjects colonized with P.
aeruginosa, while there was no relationship in subjects who were not colonized
with the organism. We also found that these changes were associated with
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changes in the Th1/Th2 balance in the lungs of these subjects [115]. While
others had previously described the role of the Th1/Th2 polarization in CF, we
were the first to assess macrophage polarization in these patients. This research
continues our previous work to assess gene markers associated with
inflammation, macrophage phenotype, and fibrosis. We hypothesized that
inflammatory genes would be associated with improvements in lung function in
these patients, and that AZM treatment would be associated with a shift in gene
expression towards the M2 phenotype in these patients.

B. Detailed methods
Clinical design
Subjects were recruited from both the pediatric and adult cystic fibrosis
clinics at the Kentucky Clinic at the University of Kentucky Chandler Medical
Center, during routine clinic visits. For inclusion, patients diagnosed with CF
were to be between the ages of 2-50 years, and not be in an acute exacerbation
of their disease. This determination was made by the treating pulmonologist.
Patients were ineligible to participate in the study if they were experiencing an
acute exacerbation of their disease at the time of initial sample collection (e.g. a
clinically relevant decline in FEV1% predicted since their previous appointment,
or if their disease required hospitalization to treat their symptoms). Additional
exclusion criteria included any active infectious process, malnutrition, HIV
infection, cancer, or women who were pregnant or breastfeeding. Subjects 18
and older were consented, while the parents of subjects under the age of 18
signed parental consent forms, and the subjects signed assent forms. All
patients or their legal guardians additionally signed HIPAA waivers to allow us to
perform chart reviews at a later date.
Sample collection
Sputum samples were collected from patients at both the pediatric and
adult cystic fibrosis clinics at the Kentucky Clinic. The University of Kentucky
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Institutional review board allowed us to collect samples during normal follow up
clinic visits. Patients were asked to provide a spontaneous sputum sample
during the course of a routine clinic visit. Samples were collected within 30
minutes of lung function tests being performed. Samples were immediately
placed on ice and transported to the laboratory, at which time 5 ml of PBS was
added, followed by the addition of 5 ml of digestion buffer (0.1% DL-Dithiothreitol
[Promega, Madison, WI] + 50 units/ml Deoxyribonuclease I [Sigma Aldrich, St.
Louis, MO]). Samples were then incubated for 30 minutes at 37°C, with shaking
every 5 minutes to aid in the digestion. After incubation, samples were
centrifuged for 7 minutes at 1200 RPM. The incubation process was repeated
once if the sample was deemed to still be overly viscous. Cells were
enumerated, and aliquots were collected for cytospin and Diff-Quick staining.
Cells were placed in RNAlater (Ambion, Austin, TX), and frozen at -80°C for
subsequent analysis. Spontaneously provided sputum samples are composed of
macrophages, neutrophils, and epithelial cells. Epithelial cell contamination is
one of the weaknesses associated with the collection of sputum samples.
RNA isolation
Digested sputum samples were thawed and RNAlater was removed.
Cells were lysed utilizing Qiashredders and RNeasy mini-kits (Qiagen, Valencia,
CA), and samples were processed according to the provided protocols. Samples
were initially lysed in 600ul of buffer RLT, containing guanidinium thiocyanate,
and finally suspended in 30ul of nanopure water. RNA was quantified using a
Nanodrop 2000 (Thermo Scientific, Wilmington, DE). RNA samples were frozen
at -80°C for future analysis.
Generation of cDNA
Reverse Transcription was performed utilizing materials from Applied
Biosystems (Foster City, CA). A set amount of isolated mRNA was incubated
with a reverse transcriptase cocktail consisting of 5.5 mM magnesium chloride,
500μM deoxy NTP, 2.5μM random hexamers, 0.4U/μL Rnase inhibitor, 1.25U/μL
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MultiScribe Reverse Transcriptase, and TAQMAN RT buffer. Incubation
conditions were 10 minutes at 25°C, 30 minutes at 48°C, and finally 5 minutes at
95°C. cDNA was frozen at -80°C until ready for quantitative real-time PCR.
Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed on the samples for a variety of gene markers of
M1 and M2 polarization, as well as inflammation and fibrosis. TAQMAN gene
probes (Applied Biosystems, Foster City, CA) were used for analysis. A
complete list of genes probed for is given in table 4.1. These genes were chosen
to allow us to examine the net macrophage polarization, as well as the total
inflammatory and fibrotic profile of the cells in the sputum samples. Samples
were run in triplicate for each gene. The final volume for each sample was 20μL,
consisting of TAQMAN universal PCR MasterMix (Applied Biosystems, Foster
City, CA) and TAQMAN gene probes in concentrations suggested by the
manufacturers. Samples were run utilizing an ABI 7900 HT fast real time PCR
system (Applied Biosystems, Foster City, CA), and the amplification phase of the
reaction was run for 50 cycles. The complete cycling parameters can be seen in
table 4.2. Gene expression was calculated as 2^-(average Ct gene of interestaverage Ct GAPDH).
Statistical analyses
Principal component analysis (PCA) was performed as a method of data
reduction utilizing the statistical software package SPSS (IBM, Chicago, IL).
PCA allows the creation of new variables comprised of combinations of the
previously collected data. These new variables are weighted based off of the
correlations between the various genes. The output is designed such that the
first newly generated variable (or “component”) explains the highest amount of
the total variance between the initial genes; the second component explains the
next highest amount of total variance, and so forth. Generated components were
deemed to explain a significant amount of the total variance if they had an
eigenvalue greater than 1. Additional statistical analysis was performed utilizing
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Graphpad Prism (GraphPad software, La Jolla, CA). Comparisons between
groups was made via one way ANOVA with Tukey’s multiple comparison test for
ratio level data, and by Fisher’s exact test for nominal data.
C. Results and discussion
Subject demographics
Thirty patients were recruited for the study, with a total of 66 samples
collected from September 2009 to December 2010. We collected 30 original
samples, 18 first follow-up samples, 12 second follow-up samples, 4 third followup samples, and 1 fourth follow-up sample. Subject demographics are shown in
Table 4.3. Of particular note is the large percentage of patients that are taking
AZM. While not yet considered as standard of care, AZM’s use is wide-spread in
patients with CF who are chronically colonized with Pseudomonas, a practice
that is anticipated to become standard of care in the near future [14]. Additionally
we observed that a large number of our subjects were receiving other antibiotics
to control their disease progression. This is commonly done by utilizing two
antibiotics in an alternating month schedule, to attempt to prevent acute
exacerbations of their disease. Treatment with other antibiotics may conceivably
be altering macrophage polarization and therefore confounding our results.
Interestingly, among our subject population was a higher percentage of
individuals who were colonized with S. aureus than patients who were colonized
with P. aeruginosa. This is most likely due to the large amount of patients that
we have in the study who are under the age of 18. While P. aeruginosa
eventually becomes the most significant pathogens in patients with CF, younger
patients are more likely to be colonized with S. aureus [11]. And, S. aureus is
considered an emerging pathogen in this patient population, as the incidence of
colonization and infection grows [116].
Correlations between macrophage, inflammatory, and fibrotic gene
markers
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We first assessed whether there were linear correlations between gene
markers of macrophage phenotype, and markers of inflammation and fibrosis.
While the relationship between macrophage polarization and expression of
various inflammatory and fibrotic markers has been established in many disease
states, there is no evidence examining gene expression from cells isolated from
the lungs of subjects with CF. We first assessed the correlations between all of
our gene expression values, to attempt to find significant relationships. We first
assessed the correlation between TLR4, a marker of M1 activation, and the
inflammatory marker IL1α and the pro-fibrotic marker TGFβ. We found a linear
correlation between TLR4 and IL1α gene expression (Figure 4.1 A.) (R2=0.3901,
p<0.0001). This confirms the relationship that others have shown between
markers of M1 activation and inflammatory cytokine production. We observed
similar findings between TLR4 and TGFβ (Figure 4.1 B.) (R2=0.5037, p<0.0001).
While at first glance it may seem counterintuitive to find a linear relationship
between a marker of M1 macrophage activation and an anti-inflammatory, profibrotic marker, it is important to note that when subjects are not in an acute
exacerbation of their disease, there is homeostasis that occurs in the lungs of
these subjects in a balance of both pro- and anti-inflammatory markers. We also
found a linear relationship between gene expression of the pro-inflammatory
cytokine TNFα and the fibrotic protein fibronectin (Figure 4.1 C.) (R2=0.2575,
p<0.0001). Much of the reason for damage that occurs in the lungs of patients
with CF is due to an overly zealous initial inflammatory response. One of the
potential methods by which AZM improves lung function in these subjects is by
shifting macrophage polarization from the M1 to the M2 phenotype, and
decreasing the amount of damage done by the initial inflammatory response to
an infection.
We next examined the relationship between markers of M2 activation and
genes associated with fibrosis. We were interested in determining if markers of
alternative macrophage polarization correlated with fibrotic markers in our subject
population, including subjects taking AZM. We found a linear relationship
between CCL-18, and fibronectin gene expression (Figure 4.1 D.) (R2=0.3341,
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p<0.0001). We found an extremely strong linear relationship between MR and
fibronectin gene expression (Figure 4.1 E.) (R2=0.8981, p<0.0001). CCL-18 is
upregulated in M2 macrophages, resulting in chemotaxis of T-cells and activated
monocytes and dendritic cells [117]. While not surprising, it is encouraging to
see that this relationship still holds strong in the lungs of subjects with CF. As we
have seen previously, this relationship seemingly suggests that an M2
macrophage polarization may exert a deleterious effect on the lungs of subjects
with CF, and seems to imply that AZM is not beneficial in these subjects. Again,
however, the other possibility is that AZM is blunting the initial inflammatory
response to infections in the lungs of subjects with CF, resulting in less damage
to be repaired in the lungs of these subjects. Finally, we found a linear
relationship between gene expression of MR and IL10 (Figure 4.1 F.)
(R2=0.2411, p<0.0001). While not surprising, it is encouraging to observe that
gene expression of the anti-inflammatory cytokine IL10 was correlated with gene
expression of markers of M2 macrophage activation. We did not observe any
other significant relationships for the expression of these genes. This again
shows that the M2 macrophages that we observe in subjects with CF are
phenotypically similar to M2 macrophages that have been observed by others.
Impact of azithromycin treatment and age on gene expression, clinical
parameters
We next assessed the impact of clinical parameters, including treatment
with AZM, upon gene expression associated with macrophage polarization. We
did this by utilizing data not only from initial visits, but from all subject samples
collected. By doing so we were able to increase the power of our analysis.
Additionally, it was necessary to do this in order to increase the number of
samples from subjects not on AZM. We first examined differences in lung
function between subject groups stratified by various parameters. Figure 4.2 A.
shows FEV1% predicted for subjects stratified on the basis of AZM therapy at the
time of sample collection. We found that FEV1% predicted in patients taking
AZM was statistically significantly lower than that of patients who were not
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receiving AZM. This is almost certainly due to the fact that as patients advance
in their disease progression, they are more likely to be placed upon long-term
AZM therapy. Similarly, adult patients displayed significantly decreased FEV1%
predicted when compared to pediatric patients (Figure 4.2 B.). Again, this
difference is likely due to routine decline in lung functions that occur as patients
age. Finally, figure 4.2 C. depicts the impact of stratification by AZM therapy in
both age groups individually. Here we can see that most of the differences in
FEV1 % predicted observed in the previous two graphs lie within the pediatric
subgroup. There were essentially no differences between adult patients
receiving or not receiving AZM. However, the low number of samples from adult
patients who were not receiving AZM makes comparisons difficult, as the chance
of a type II error is high.
We next assessed NOS2 and ARG1 gene expression in our patient
populations. NOS2 is widely considered to be one of the prototypical markers of
classical macrophage activation [1, 3]. ARG1 is similarly considered to be a
marker of M2 activation in mice, there is, however, evidence that it may be a less
significant marker of M2 activation in humans [118]. Figure 4.3 A. shows
differences in NOS2 gene expression between subjects who either did or did not
receive AZM. We found a significantly lower expression of NOS2 in subjects
treated with AZM. We observed the opposite trends for ARG1 gene expression,
as it was increased in subjects receiving AZM (Figure 4.3 B.). While we did not
observe statistically significant differences between the two groups for ARG1
gene expression, this may be due to having insufficient power to detect the
differences between the two groups. Due to the time consuming nature of
subject recruitment, as well as the expense associated with processing subject
samples, we limited ourselves to 30 subjects for this study.
When we separated the samples not only by AZM status, but additionally
stratifying subjects by age, additional interesting observations were made. In
figure 4.3 C. we can see that the difference in NOS2 gene expression is most
pronounced in our pediatric subjects, with almost all of our pediatric subjects
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receiving AZM having little to no gene expression of NOS2. When we examined
ARG1 gene expression, however, we found that this difference is most
pronounced in our adult subject population, and less pronounced in our pediatric
population. While we did notice trends in ARG1 gene expression in our adult
subjects who were either on or off AZM, we did not observe significant
differences. These two findings suggest that AZM is able to polarize
macrophages to an alternatively activated phenotype in the sputum samples that
we collected. It is important to note that there is a great deal of variability in gene
expression between our various samples, which may explain the difficulty that we
had to obtain statistical differences between the groups.
We then compared expression of other inflammatory, fibrotic, and M2
genes between subject groups stratified on the basis and AZM treatment. We
found a trend towards a decrease in gene expression for the pro-inflammatory
cytokine IL1α (Figure 4.4 A.) (p=0.1241), suggesting that AZM may be
decreasing pro-inflammatory cytokine expression among our subject population.
We also found a non-significant decrease in fibronectin gene expression (Figure
4.4 B.) (p=0.2947). When we assessed other gene markers for M2 activation, we
found no differences in CCL18 gene expression (Figure 4.4 C.), and a slight
decrease in MR gene expression (Figure 4.4 D.) (p=0.0835). The slight
decrease in IL1α gene expression in subjects who were receiving AZM further
describes ways that AZM appears to benefit these subjects. More difficult to
explain, however, is that we observed no differences in gene expression for
CCL18, and even a slight decrease in MR gene expression in subjects treated
with AZM. It is possible that this is due more to the types of subjects who are
likely to be receiving AZM, e.g. subjects with more severe declines in lung
function are more likely to have impaired expression of the genes that we
assessed. The small degree of differences that we observed, well above
statistical significance, however, makes it difficult to truly assess any differences
among these samples.
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Finally we assessed gene expression related to the clinical parameters
used to measure lung function and disease progression, FEV1 and FVC (forced
vital capacity) % predicted. While we did not observe significant correlations
among any of the gene expression values and FEV1% predicted, we did find
significant linear correlations between FVC % predicted and the inflammatory
cytokines IL1α and TNFα (Figure 4.5 A. and figure 4.5 B.). This suggests that
declines in lung function are associated with a decrease in gene expression for
these pro-inflammatory M1 related cytokines. This can potentially be explained
by the shift that occurs over time in the lungs of CF subjects from a Th1 dominant
polarization to more of a Th2 polarization. It may also be due to a decline in the
number of cells in the lungs of subjects who have been long colonized with
bacteria, with a resulting decrease in the mRNA that we were able to collect from
the subjects. It may also be due to changes in the profiles of cells that are
present in the lungs of the subjects as lung function declines. Interestingly, we
also found a linear correlation between FVC % predicted and gene expression of
the anti-inflammatory cytokine IL10 (Figure 4.5 C.). This gene is most likely
upregulated in order to ensure that the inflammatory response does not become
dysregulated. Similarly to the inflammatory cytokines, it may also be a response
that as lung function declines in subjects with CF the cells are less robust than
they are in subjects with better lung function.
Principal component analysis and gene grouping
To this point, we have been able to make observations in how the
expression of certain genes of interest varies among our subjects, and how gene
expression indicative of macrophage phenotype polarization relates to markers of
inflammation, fibrosis, and clinical indices. However, these previous analyses do
not present a robust profile that can correlate a certain macrophage gene
expression profile to the clinical parameters (including AZM therapy) of our
subject population. In order to determine whether such a description can be
purported, we utilized principle component analysis (PCA) to simultaneously
examine the expression variability of all genes measured.
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An initial round of PCA was performed using the gene data from the initial
clinic visit for each subject only. This is because PCA requires independence
among all data measurements. All 15 genes of interest were included in the first
round of analysis. This first round of PCA created 5 components. The weighting
of genes in each component for this analysis shown in Table 4.4. Component 1
accounted for 32% of the total variance of the gene samples, while component 2
accounted for an additional 18% of the total variance. Components 3, 4, and 5
explained an additional 12%, 10%, and 7% of the total variance for these genes,
respectively. We found 4 genes with a high weighting in component 1 and a low
weighting in component 2. Conversely, we determined that an additional 4 genes
were weighted high in component 2, and a low in component 1. These groupings
explain genes with expression that vary in a similar manner, showing that these
genes are associated with each other.
This is especially interesting when one considers the function of the genes
that were grouped together in the process of creating the first 2 components.
The genes MMP9, NOS2, TGFB, and TLR4 had high weighting in component 1
and low weighting in component 2. NOS2 and TLR4 both are traditionally
associated with the M1 phenotype [3]. CCL18, fibronectin, IL12b, and MR were
highly weighted in component 2, and had a low weighting in component 1.
CCL18, fibronectin, and MR are traditionally associated with the M2 phenotype
[3]. That the gene weightings generally grouped in a manner consistent with
either an M1 or M2 activation confirms the validity of utilizing PCA. Component 1
did contain some M2 associated genes, contrariwise component 2 contained
some genes traditionally associated with inflammation. It is important to note,
however, that the inflammatory profile in the lungs of these patients is dynamic.
Anti-inflammatory genes may be up-regulated in the aftermath of an inflammatory
flare, and vice versa. Interestingly, arginase 1 was not strongly associated with
any of the components. This is consistent with findings from others suggesting
that while arginase 1 is an important marker of macrophage polarization in mice,
it may be a less important marker in humans [118]. We did, however, find other
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markers that are traditionally associated with the M2 phenotype were highly
weighted into component 2.
We next performed an additional round of PCA utilizing only the genes
that were highly weighted in either component 1 or component 2. The previous
round of PCA produced gene weighting that varied similarly among subject
samples. The second round was performed to allow us to focus just on the most
significant genes that we assessed. The gene weightings from the second round
of PCA are presented in figure 4.5. Utilizing the restricted gene set, 2
components were generated. These two components were responsible for 39%
and 34% of the total variance among the 8 genes in the restricted gene set,
respectively. The weightings from these two components were utilized to
generate individual values for each sample. These two generated components
were utilized for the next series of analysis.
Subject clinical data stratified via PCA components
We plotted the values for components 1 and 2 for each initial subject visit,
as shown in figure 4.6. One of the basic assumptions of PCA is that each
component is orthogonal to every other component; that is, there should be no
correlations between individual components. This allows us to graph the two
components, and determine if individual subjects group together. We found that
the subject samples sorted into three distinct groups. There was first a group of
subjects that had low values for both component 1 and component 2. It is
reasonable to assume that macrophages in these patients were not polarized to
either the M1 or M2 phenotype. Next, there was a group of subjects that had a
higher value in component 1 than component 2. These patients are considered
to have had a macrophage profile that was polarized more toward that of an M1
phenotype. Finally, there was a group of subjects that had a higher value in
component 2 than component 1. The macrophage populations of these
individuals can be considered to have a net M2 polarization.
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We first assessed AZM status in each of the three groups to see if this
differed according to macrophage gene expression status. Figure 4.7 A. shows
the percentage of patients in each of the three groups that were taking AZM.
According to these results, AZM therapy did not influence the gene expression
profile as stratified by PCA (p=0.6465, Fisher’s Exact Test). It is important to
note, however, that the percentage of patients taking AZM was extremely high in
all three groups. As patient lung function declines, clinicians at the University of
Kentucky CF clinics are extremely likely to place the patients on the drug. Due to
this, it made it difficult to assess the impact of AZM therapy in this analysis.
Figure 4.7 B. shows the average age of subjects in the three groups. We
found that patients with a high PC2 value (M2-biased) were significantly older
than patients who were high in PC1 (M1-biased). This is consistent with data in
the literature showing that a Th2 polarization increasingly persists in the lungs of
patients with CF as they age [32]. This Th2 polarization likely would correlate
with an increase in polarization of macrophages to the M2 phenotype, and
suggests a possible explanation for why we observed that patients who had
higher gene expression of M2 markers were significantly older than patients with
high gene expression of M1 markers.
We next compared lung function of subjects in the three groups. Figure
4.8 A. shows that there were no differences in the mean FEV1% predicted
between the three groups.

Figure 4.8 B. shows the FVC % predicted. Here

again we did not observe a difference in this parameter between the three
groups. We had initially anticipated that there would be differences between the
component 1 high and the component 2 high groups. This data suggests that
macrophage phenotype does not correlate to baseline lung disease severity in
these patients, as analyzed by this variable reduction process.
We then compared additional antibiotic use among the three groups.
Patients with CF are routinely placed on other antibiotics as a means to either
treat acute exacerbations or limit their incidence. Figure 4.9 shows non-AZM
antibiotic use between the three groups. We first assessed the percentages of
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patients receiving oral and IV antibiotics other than AZM for their disease (Figure
4.9 A.). We found that patients that had high values for component 2 were less
likely to be taking other antibiotics than patients with low values for both
components (Fisher’s Exact Test, p=0.0932). We observed a similar trend in
patients with high values in component 1 (p=0.0809), but the results were not
significant, due in part to the relatively small number of patients in the group. We
next assessed the percentages of subjects receiving inhaled tobramycin therapy
(Figure 4.9 B.). Inhaled tobramycin is commonly used to control pulmonary
infections in patients with CF, most notably for patients colonized with P.
aeruginosa [14]. We observed similar trends in inhaled tobramycin usage as we
did in the non-AZM antibiotic usage in these subjects. Namely, patients with high
values for component 2 appeared to be less likely to receive inhaled tobramycin
than patients with either high values in component 1 or with low values for both
components. There are a few possible explanations for this. First, patients with
either polarization to the M1 or M2 phenotype may be innately more stable in
their disease, and be less likely to require other antibiotics than patients whose
macrophages are inactive. Second, treatment with other antibiotics may be
helping to keep bacteria at a state where a robust macrophage response of
either phenotype may not be necessary. Unfortunately, due to the nature of the
data that we collected for this study, it is impossible to determine which of these
two possibilities is the case for our patients with CF.
Lastly, we assessed the bacterial colonization status among our PCAstratified subject groups. Figure 4.10 presents the percentages of subjects that
were colonized with either P. aeruginosa or S. aureus. Due primarily to the
difficulty that CF patients experience in clearing infectious pathogens from their
lungs once they have been infected, subjects were deemed to be colonized with
one of the two bacteria if the last recorded sputum cultures in their charts showed
a positive culture. We did not find statistically significant differences in bacterial
colonization between the three groups. One of the initial assumptions of PCA
(sample independence) prevented us from utilizing all 66 of our samples,
restricting us to just the initial visits for the 30 subjects. The smaller number of
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samples likely prevented us from being able to find significant differences
between the three groups. The trends that we observed, however, were very
intriguing. Most interestingly, subjects with high values in component 2 were
more likely to be colonized with P. aeruginosa, but less likely to be colonized with
S. aureus. The reason for these differences in bacterial colonization status is
unclear. When considering our population, subjects with high values for
component 2 were significantly older than patients with high values for
component 1. P. aeruginosa becomes the most significant pathogen in patients
with CF as they age, with studies suggesting colonization rates in excess of 80%
in adult patients [11]. Contrariwise, younger subjects are more likely to be
colonized with S. aureus [11]. There is also evidence that the microbial infection
patterns are changing across the United States in subjects with CF. One of
these shifts is a greatly increased rate of colonization (upwards of 20%) with S.
aureus, especially MRSA [116, 119]. Additionally, evidence exists that the rates
of P. aeruginosa colonization have been declining in patients with CF, on the
order of 5-6% in most patient age ranges over the time span from 1995-2005
[116]. These differences in bacterial colonization rates in patients over time may
suggest a possible explanation for the differences seen in the three groups.
Another possibility, however, is that the pathogens themselves are playing a role
in macrophage polarization, or that different macrophage polarizations may be
more beneficial in subjects colonized with one of these two pathogens.
D. Conclusions
General Conclusions
In these experiments we present data suggesting a possible mechanism
by which AZM benefits patients with CF. By utilizing PCA, we were able to
observe 2 distinct gene groupings consistent with an M1 or an M2 macrophage
polarization. By utilizing these two distinct components, we were able to place
our subjects into three different groups, and assess clinical parameters for these
subjects. Disappointingly, we were not able to determine whether AZM treatment
correlated with one or more groups. We believe that this is primarily due to the
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high prevalence of subjects receiving AZM in our study. Future consideration of
the duration of treatment with AZM for subjects may enhance this analysis. It
was also intriguing that we did not observe differences in FEV1 % predicted
between the three groups. While we focus on the role of AZM in these subjects,
there are also a wide variety of other treatments that these subjects are taking to
improve their lung function, both pharmacologic and non-pharmacologic, and the
effects of these other treatments may be overwhelming our ability to tease out
the effects of AZM. While AZM therapy did not influence the stratification of
subjects here based upon macrophage-related gene expression, it has been
shown by others in the past to improve parameters in patients with CF [16, 18,
20]. We were, however, able to show gene groupings that are consistent with
either an M1 or an M2 macrophage polarization. This suggests that differences
in macrophage polarization do exist in these subjects.
It was also interesting to observe the gene groupings in our two principal
components. Our first component consisted of MMP9, NOS2, TGFB, and TLR4.
NOS2 and TLR4 have traditionally been very strongly associated with the M1
phenotype. MMP9, a metalloprotease, is associated with cleavage of the fibrotic
proteins, and can be considered in terms of its role as a marker of remodeling
and ECM turnover. While it has been linked to the M1 phenotype in the past, this
data further links MMP9 with other M1 associated genes. PCA groups genes
with similar variances, and finding MMP9 associated with genes strongly
associated with the M1 phenotype strongly suggests that MMP9 gene expression
is upregulated as part of the gene expression profile of M1 macrophages. In our
second principal component, we found strong weightings for the genes CCL18,
fibronectin, IL12b, and MR. CCL18 and MR have traditionally been strongly
associated with the M2 phenotype. Finding fibronectin expression to be
associated with other M2 associated genes was additionally not particularly
surprising. This upregulation in fibronectin expression associated with M2
macrophages could additionally explain why the Th2 phenotype is associated
with declining function in subjects with CF as they age.
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Most intriguing are the differences that we observed in bacterial
colonization status for subjects in the three groups, as well as the differences that
we observed in age between the three groups. Subjects with high values for M2
gene markers were significantly older than subjects with high values for M1 gene
markers, suggesting a shift towards the M2 phenotype as subjects age. While
consistent with observations from others showing a Th2 polarization over time in
patients with CF, it was interesting to see that this observation holds true for
macrophages as well. Additionally, the differences we observed in bacterial
colonization status may illustrate the shifting patterns of bacterial colonization
that is occurring in patients with CF. Differences in bacterial colonization may
also be driving differences that we observe in macrophage polarization.
At first glance, much of this data seems to suggest that treatment with
AZM may be deleterious in many patients. Namely, we showed that in our
subject population, pro-inflammatory cytokine gene expression was increased
with higher values for lung function. Treatment with AZM results in decreased
inflammatory markers as well as an upregulation in a cell type that produces
fibrotic proteins. This would seem to suggest that AZM may potentially result in
harm in patients with CF. However, we also observed that AZM resulted in
decreases in NOS2 gene expression. The M2 shift, therefore, results in a
decrease of genes necessary for the oxidative burst to destroy bacteria. This
oxidative burst, however, leads to damage in the airway, both during an acute
flare of the disease, and during the resting state of the disorder. In light of the
beneficial effects that patients with CF have long reported with AZM, another
possibility presents itself. By shifting macrophage polarization away from the
inflammatory M1 phenotype, and towards the pro-fibrotic M2 phenotype, this may
be resulting in less oxidative damage occurring in the lungs of these patients.
The decrease in damage may then result in less need for repair from the M2
phenotype, and a resultant decrease in scarring and fibrosis.
Limitations
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There are several limitations associated with the data generated here.
First, not all patients with CF are able to provide sputum samples. Sputum
production becomes more likely as subjects age. Very young patients, as well as
patients with mild disease are less likely to be sputum producers. Thus, while
our age range for subjects in our study was technically between the ages of 2-50,
the youngest subject that we recruited in the study was in fact 8 years old. This
also results in our data being skewed towards older, less healthy subjects. This
is also in part likely one of the reasons why a large amount of our subjects were
on AZM.
Additionally, there is considerable variability in the quality of sputum
samples that subjects provide. While sputum samples consist predominately of
monocytes, macrophages, and neutrophils, low-quality samples can also have
considerable epithelial cell contamination. Some studies exist that suggest that
the percentage of epithelial cells in collected sputum samples in patients may
range from 20%-50% [120, 121]. Additionally, for gene analysis, having mRNA
from a more representative sampling of cells in the lungs might allow us a better
picture of the inflammatory and fibrotic state of these subjects.
The ideal method for acquiring cell from the lungs of patients is by
bronchoalveolar lavage fluid (BALF). BALF samples are considerably more pure,
with a much higher percentage of monocytes and macrophages than sputum
samples, and essentially no epithelial cells [122]. This procedure, however, is
extremely invasive, requiring specialized training, as well as heavy anesthesia.
Additionally, there are risks associated, including fever, pneumonitis, bleeding,
and bronchospasm [123]. This results in BAL primarily being perfomed for
patients who have been admitted to the hospital for an acute exacerbation of
their disease. Since we were interested in the status of patients who were at a
baseline state of pulmonary function, we were unable to collect samples in this
manner. Ultimately, we felt that the disadvantages of collecting only sputum
samples from these patients were outweighed by the advantages of being able to
easily collect cells in a minimally invasive manner during a routine clinic visit.
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We were additionally surprised to observe that such a large amount of our
subjects were taking AZM. From our previous work, we had anticipated that we
would have fewer subjects that were taking the drug. In our previous studies we
found that only 65% of the subjects were taking AZM [115]. Here, almost 80% of
our subjects were being treated with AZM. The high rate of AZM usage in our
subjects made it difficult to determine the significance of the impact that the drug
may exert on macrophage gene expression. We hope in the future to be able to
have subjects stop taking AZM, and compare gene expression in the subjects
when they are on AZM to when they are not receiving the agent.
We were unable to record the duration that subjects were taking AZM due
to the nature of our chart reviews. It would have been interesting to assess how
duration of AZM treatment in our subjects grouped with our principal component
analysis, to determine whether duration of AZM treatment was associated with
gene expression in our subjects. Additionally, we were unable to take subjects
off of AZM for the purposes of our study. We plan to do this in the future.
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Table 4.1. List of genes utilized for qRT-PCR. Data also includes
classification of the role of the gene, the abbreviation utilized throughout this
chapter, and the product number.
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Table 4.2. Cycling parameters utilized for qRT-PCR
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Table 4.3. Demographics of subjects enrolled in the study.
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Figure 4.1. Gene expression correlations in sputum samples from subjects with
CF. Sputum samples from CF patients were collected, and mRNA was isolated.
Gene expression was assessed via qRT-PCR, and values for the genes of
interest were normalized to expression of the housekeeping gene GAPDH.
Panels represent (A) Correlation between TLR4 and IL1α; (B) TLR4 and TGFβ;
(C) TNFα and fibronectin; (D) CCL-18 and fibronectin; (E) MR and fibronectin;
and (F) MR and IL10. Gene samples were run in triplicate, and average value
for each gene was plotted. R square and p values are listed below each graph.
Linear regularity was assessed with Graphpad Prism.
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Figure 4.2. FEV1% predicted compared for both subject AZM status and
subject age. FEV1 % predicted was compared to (A) AZM usage; (B) subject
age; (C) both age and AZM usage. FEV1% predicted was collected from chart
review. Statistical analysis was performed via either an unpaired t-test, or a
one-way ANOVA with Tukey’s multiple comparison test, where appropriate.
Differences were deemed to be statistically significant with a p value <0.05
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Figure 4.3. Expression of prototypical M1 and M2 genes in subjects receiving
AZM. Sputum samples from subjects with CF were collected, and mRNA
isolated. Gene expression was assessed via qRT-PCR, and normalized to the
housekeeping gene GAPDH. Panels (A) and (B) are stratified to AZM usage,
and are compared to either (A) the M1 gene marker NOS2; or (B) the M2 gene
marker ARG1. Panels (C) and (D) are stratified with both AZM usage and
subject age, and are compared to (C) NOS2; or (D) ARG1. Statistical analysis
was performed via either an unpaired t-test, or a one way ANOVA with Tukey’s
multiple comparison, where appropriate. Differences were deemed statistically
significant with a p value <0.05.
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Figure 4.4. Gene expression of M1 and M2 associated genes in subjects
with CF. Sputum samples from subjects with CF were collected, and mRNA
was isolated. Gene expression was assessed via qRT-PCR, and gene
expression was normalized to the housekeeping gene GAPDH. Panels are
stratified in terms of AZM usage, and consist of (A) the M1 gene marker IL1-α;
(B) the fibrotic gene marker fibronectin; (C) the M2 gene marker CCL18; (D)
the M2 gene marker MR. Statistical analysis was performed via an unpaired
t-test. Statistically significant differences were not observed between any
groups.
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Figure 4.5. Correlation between FVC% predicted and M1 and M2 associated
genes. Sputum samples were collected from subjects with CF, and mRNA
was isolated. Gene expression was assessed via qRT-PCR and normalized to
the housekeeping gene GAPDH. FVC % predicted (determined via chart
review) was compared to (A) IL1α; (B) TNFα; (C) IL10. Gene samples were
run in triplicate, and average value for each gene was plotted. R square and p
values are listed below each graph. Linear regularity was assessed with
Graphpad Prism.
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Table 4.4. Component matrix for the first round of PCA. Data was assessed
via principal component analysis. Component 1 and component 2 explained
31.8% and 18.7% of the total variance in gene expression. An eigenvalue >1
was required for inclusion of the components that were generated.
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Table 4.5. Component matrix for the second round of PCA. Genes with a
high weighting in either component 1 or component 2 were included in the
second round of PCA. Data was assessed via principal component analysis.
Component 1 and component 2 explained 38.8% and 33.6% of the total
variance in gene expression. An eigenvalue >1 was required for inclusion of
the components that were generated.
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Figure 4.6. Plotting of principal components 1 and 2. Components 1 and 2
were graphed, and subjects were divided into one of three groups:one group
with low values in both components 1 and 2, one group with greater values in
component 1 than component 2, and one group with greater values in
component 2 than component 1.
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Figure 4.7. Subject demographics with PCA subgroups. Panel (A) describes
the percentage of subjects who were receiving AZM; Panel (B) describes subject
age. Statistical analysis of percentage of subjects receiving AZM was performed
with Fisher’s exact test for each possible comparison. Subject age was analyzed
with a one way ANOVA with Tukey’s multiple comparison test. Panel (B)
represents mean ± SD for all samples.
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Figure 4.8. Parameters of lung function in PCA subgroups. Panel (A)
describes FEV1% predicted in the three subgroups; (B) FVC% predicted in the
three subgroups with PCA. Parameters of lung function were determined from
chart review. Data represents mean ± SD of all samples. Samples were
analyzed with a one way ANOVA with Tukey’s multiple comparison test.
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Figure 4.9. Other antibiotic usage in PCA subgroups. Panel (A) represents
non-AZM oral and IV antibiotic usage in subjects receiving AZM. Antibiotic
usage was determined from chart review. Statistical analysis of percentages
were performed with Fisher’s exact test for each possible comparison.
Samples were deemed statistically significant with a p < 0.1.
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Figure 4.10. Bacterial colonization rates in PCA subgroups. Panel (A)
represents the percentages of subjects colonized with P. aeruginosa; Panel
(B) represents the percentages of subjects colonized with S. Aureus.
Colonization rates were determined via chart review. Statistical analysis of
percentages were performed with Fisher’s exact test for each possible
comparison. Samples were deemed statistically significant with a p <0.05.
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Chapter 5: Discussion
A. Results Overview
The goal of this work was to further identify the mechanism and
importance of AZM dependent macrophage polarization. This was accomplished
through a combination of cell culture, animal work, and clinical research. We
utilized a series co-culture experiment to assess the importance of AZM
dependent macrophage polarization on fibrogenesis in fibroblasts. We
additionally examined the importance of AZM polarized macrophages in the
context of P. aeruginosa pneumonia in the lungs of various mouse strains. We
finally assessed gene expression in subjects with CF, and correlated gene
expression to clinical parameters.
Further description of the phenotype of azithromycin polarized
macrophages
We first assessed the ability of AZM to polarize macrophages to the M2
phenotype in the presence of both another cell type (fibroblasts), as well as in the
presence of viable bacteria. This was done to confirm the results that we had
previously seen in vitro [63]. While previous studies in our laboratory were
descriptive in examining the effects of the drug on macrophages, here we extend
the work to examine the function of macrophages treated with AZM, through both
co-culture experiments to study the interaction with fibroblasts, and through our
in vivo infection model. We confirmed through both the arginase assay and
expression of the surface molecule MR that the macrophages in both our coculture system and in infected mice are polarized by the drug to an M2-like
phenotype.
We next examined expression and activation of the pro-fibrotic molecule
TGFβ. Here we found that AZM increased both levels of active TGFβ, as well as
the ratio of active to total TGFβ, and the amount of TGFβ1 mRNA. Work from
others in our laboratory suggests that these increases in TGFβ activation are due
at least in part to increases in molecules that cleave TGFβ from its inactive to
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active form, including MMP9. Consistent with our findings for TGFβ, we found
increases in fibronectin in the co-culture system, showing that AZM polarized
macrophages act in a matter consistent with what we would expect from M2
macrophages. This suggests that function of AZM-induced macrophages is
similar to that of cells polarized by IL4 and IL13.
Importance of M2 macrophages in response to P. aeruginosa pneumonia
We examined the role of M2 macrophages in P. aeruginosa pneumonia
both in C57bl/6 mice as well as in IL4rαKO mice. In our C57bl/6 mice we found
that AZM treatment resulted in greater numbers of cells expressing M2 markers,
and fewer cells expressing M1 markers, as well as increased arginase activity.
We further found that AZM shifts the influx of cells in the lungs of these animals
away from a neutrophilic response, and towards a more monocytic cellular
response. Importantly, C57bl/6 mice treated with AZM had significantly lower
mortality from the infection, as compared to mice that did not receive AZM, while
observing essentially no differences in the numbers of bacteria present in their
lungs. We hypothesize that the shift away from the M1 phenotype and towards
the M2 phenotype is responsible, at least in part, for these improvements. In
essence, it is the overly zealous inflammatory response, rather than the bacteria,
which results in the mortality associated with P. aeruginosa pneumonia in this
model.
We observed similar, albeit less marked findings in our IL4rαKO mice, as
well as IL4rαKO mice with cells adoptively transferred with Balb/c T cells and
macrophages. While we did not observe differences in survival between these
two groups, we did still see increases in monocytes in the lungs of animals that
received macrophage from Balb/c mice, as well as decreases in neutrophils
present in the lungs of these animals. When we treated IL4rαKO mice with AZM,
we found that AZM was still able to polarize macrophages to the M2 phenotype
in these mice. Most interestingly, we found increased localization of arginase 1
around small airways in the lungs of IL4rαKO mice treated with AZM, and
decreased expression of iNOS. The clinical relevance of this shift in specific
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location of arginase expression is potentially large. The peribronchiolar regions
are impacted the most by the repeated inflammation and repair cycle in patients
with CF, whereas the integrity of the alveoli are typically spared in this
pathophysiology. This in itself could be largely responsible for the beneficial
effects of AZM. Interestingly, other studies from our laboratory utilizing the
Pseudomonas infection model have shown that the number of
monocytes/macrophages infiltrating the airways is increased, corresponding with
a decrease in neutrophil influx here [75]. The IHC data showing the location of
heightened arginase expression supports these results. These findings show
that AZM is able to polarize macrophages to the M2 phenotype independent of
IL4 and IL13 function.
Mechanistic investigations into azithromycin-dependent M2 polarization
We further assessed the mechanism by which AZM polarizes
macrophages to the M2 phenotype in vitro. We first found that AZM was able to
increase arginase activity, a marker of M2 activation in IL4rαKO splenocytes
stimulated ex vivo. We also found that AZM decreased activation of NF-κB while
increasing levels of IKKβ present in the system. These findings suggest that one
potential mechanism by which AZM polarizes macrophage to the M2 phenotype
is IKKβ dependent, presumably via activation of IKKβ. This was further
confirmed when we treated cells with the IKKβ inhibitor IKK-16. IKK-16 was able
to decrease arginase activity with AZM treated cells, while exerting no effects on
arginase activity in cells treated with IL4/13. While not confirming an exact
mechanism for AZM dependent M2 polarization, it does further isolate molecular
targets for future examinations. From this work, it does appear that signaling
through intracellular cascades is altered, and therefore responsible for the
changes in gene expression in macrophages exposed to AZM. To extend this, it
was important for us to examine the role that IL4 and IL13 play. A possible
explanation of the changes could be that autocrine IL4/IL13 secretion was being
altered by the drug, thereby affecting the change in phenotype. This does not
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appear to be the case however, because we show that AZM will polarize cells
independently of IL4/IL13 signaling.
Phenotypic determinations in patients with CF
We collected 66 sputum samples from 30 subjects with CF and isolated
mRNA. We performed qRT-PCR on these samples for a variety of genes for
macrophage phenotype, inflammatory status, and fibrosis. We additionally
performed chart review on these subjects allowing us to review their clinical
status, as well as determine other parameters of their health. We first assessed
correlations between various genes. Here we found that gene markers of M1
and M2 polarization correlated with inflammatory and fibrotic gene markers,
respectively. We next compared various clinical parameters of the subjects.
Here we found that the FEV1% predicted was significantly lower in subjects
receiving AZM. We additionally found that older subjects had significantly lower
FEV1% predicted than those who were younger. These two findings are
consistent with the place of AZM in treatment of CF, and the decline that occurs
in these subjects as they age.
Gene expression and AZM
We then correlated various gene markers of these subjects to their AZM
treatment status. We found shifts in gene expression consistent with a shift to
the M2 phenotype in the sputum samples of these subjects, as well as
correlations between inflammatory cytokines and lung function. This confirmed
the protein data that we have previously observed [115], showing that AZM
increases markers of M2 polarization, and that in subjects with CF markers of the
M1 phenotype are associated with better outcomes. This shows the potential
importance of macrophage polarization in subjects with CF.
Principal component analysis
We finally utilized principal component analysis as a method of data
reduction. We found two groupings, with one representing genes associated with
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the M1 phenotype and one representing genes associated with the M2
phenotype. We then charted these two components, and found that our samples
sorted into three different groups. Gene expression in one group showed
markers of neither phenotype. Another group displayed increased expression of
M1 activation, while a third displayed increased expression of M2 activation.
Clinical status in these subjects was then assessed. Our findings were
consistent with those of others with the net Th2 shift that occurs in patients as
they age [32]. The cytokines produced as part of this shift result in an alteration
in macrophage polarization, as exemplified by the increased age observed in the
group with high expression of M2 markers. We additionally observed differences
in bacterial colonization between our groups, with subjects with high expression
of M1 associated genes more likely to be colonized with S. aureus, and less
likely to be colonized with P. aeruginosa than subjects with high expression of
M2 markers. This again reflects the observations of others, with the shifts we
observed in bacterial colonization status being similar to those observed by
others in the past [119]. It is unknown whether these changes are related to the
difference in macrophage polarization, or are related to the difference in subject
age between the two groups.
B. Significance
IKKβ and macrophage polarization
We attempted to further isolate molecular targets by which AZM polarizes
macrophages to the M2 phenotype. Based on the work by Fong et. al., we
assessed IKKβ as a target for AZM. Their work utilized mice that were
conditional knock-outs of IKKβ in either epithelial or myeloid cells. In mice with
the IKKβ deficiency in epithelial cells, they found decreased inflammation as they
expected. Surprisingly, however, in their mice with deficient IKKβ in myeloid
cells, however, they found increased resistance to pulmonary infections with
Group b Streptococci. They went on to find that macrophages with deficient
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IKKβ signaling displayed increased markers of M1 activation, primarily measured
by cytokine expression [68].
They then examined why eliminating IKKβ signaling in myeloid cells
would lead to increased M1 signaling. They found that STAT1 phosphorylation
was increased in cells with deficient IKKβ signaling, suggesting that IKKβ
prevents the activation of STAT1. They hypothesize that this interaction is
necessary in macrophages to allow for resolution of the immune response over
time [68].
To attempt to determine if one of the ways that AZM polarizes
macrophages to the M2 phenotype is via activation of IKKβ, we utilized a small
molecule inhibitor of IKKβ to assess if IKKβ activation played a role. We found
that inhibition of IKKβ activation with IKK-16 eliminated AZM dependent arginase
activity, while exerting essentially no effect on IL4/13 dependent arginase activity.
We did, however, find that extremely high concentrations of AZM were able to
overcome this inhibition. This further confirms molecular targets by which AZM
polarizes macrophages to the M2 phenotype. Due to technical limitations, we
were unable to confirm that AZM in fact prevents phosphorylation of STAT1,
confirming that this is the mechanism by which AZM polarizes macrophages to
the M2 phenotype. In essence we were unable to detect p-STAT1 in our cells,
including in positive controls (IFN +LPS stimulated cells). Future work in our
laboratory will focus on alternative experiments to confirm that STAT1 activation
is decreased with AZM treatment.
Breaking the cycle of inflammation and fibrosis
Disease progression in CF is characterized by repeated cycles of
infection, inflammation, repair, and fibrosis [15]. We believe that the beneficial
effects of AZM in these patients are due in part to decreasing the extent of the
immune response to an acute flare of the disease. Figure 5.1 shows our
proposed model for the beneficial effects of AZM. In the normal course of CF,
there is a large inflammatory response consisting, among other cells, of M1
142

macrophages and neutrophils [44]. This overly zealous immune response, in the
process of clearing the bacterial flare, results in the production of reactive oxygen
species which leads to tissue damage in the lungs of these patients. After the
initial inflammatory response, alternatively activated macrophages are upregulated to help initiate the repair process. These cells are responsible for
cleaning up the damage that occurred during the acute bacterial flare. They do
this in part by internalizing the debris that was produced as part of the infection.
M2 macrophages additionally up-regulate molecules leading to fibrosis, including
fibronectin and collagen [38]. This process is necessary, allowing the lungs to
repair. Excessive scarring, however, leads to a decline in airway function. This
decline, then, increases the likelihood of a future flare occurring. This cycle of
inflammation and fibrosis leads to a decline in lung function for the patient over
time, and is responsible for much of the morbidity and mortality associated with
CF.
Others have utilized similar models and observed similar findings with
AZM. Tsai et. al. have utilized a P. aeruginosa infection model with a strain of
mice with deficient CFTR function [100]. Unlike our findings, they observed that
AZM treated mice displayed fewer bacteria in their lungs. They did, however
observe a similar increase in survival and decrease in neutrophils influx as we
observed with our mice. They also observed similar alterations in inflammatory
cytokine production with their mice. While this group did not examine differences
in macrophage activation status, in conjunction with our data it supports the
hypothesis that the benefits of AZM are due in part to alterations in macrophage
polarization.
With AZM, what we believe is occurring is that the initial inflammatory flare
of the disease is being blunted. By shifting some of the macrophage polarization
away from the M1 phenotype and towards the M2 phenotype during the initiation
of inflammation, the immune response, while still strong enough to clear the
infection, does not cause the same degree of damage as the dysregulated
response would. There is then less repair and recovery necessary for the lungs
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of these patients to recover from. This model helps to explain the seeming
contradiction that exists with AZM treatment in CF. By decreasing the degree of
an initial inflammatory flare, AZM improves lung function in patients with CF,
even though it increases the amount of pro-fibrotic macrophages in the lungs.
Importance of alternatively activated macrophages in the response to
extracellular bacteria
Characterizations into the importance of alternatively activated
macrophages have primarily focused on intracellular bacteria and parasites.
Kasmi et. al. assessed the importance of alternatively activated macrophages in
host response to the intracellular pathogens Mycobacterium tuberculosis and
Toxoplasma Gondii [124]. They found that these pathogens actually up-regulate
the M2 marker arginase. This decreases intracellular arginine levels, and
prevents the generation of a robust M1 dependent oxidative burst. They
additionally utilized an Arg 1 knockout mouse, and found that these mice
survived infection with intracellular bacteria more readily than wild type mice.
They concluded that M1 macrophages play an important role in the destruction of
intracellular bacteria, while M2 macrophages allow these bacteria to evade
destruction.
Others have investigated the role of M2 produced arginase 1 with
parasites including S. mansoni. Study of the inflammatory response to S.
mansoni infection showed that mice with macrophages that lack arginase 1
succumb to Th2-driven pathology associated with the pathogen, related a lack of
inhibition of the CD4+ T cell response. They concluded that arginase played an
important role in the suppression of T cell dependent inflammation [85, 86].
Considerably less is known about the role of M2 macrophages with
extracellular bacteria. This is primarily due to M2 macrophages not being
present during the acute phase of these responses. We have shown that the
inducement of the M2 phenotype during the acute phase of an infection improves
survival in C57bl/6 mice with P. aeruginosa pneumonia. We have observed
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similar trends with IL4rαKO mice adoptively transferred with functional
macrophages. We hypothesize that this improvement is due in part to a blunting
of the robust immune response that occurs in the context of an extracellular
infection.
Future directions
While we were unable to determine an exact molecular mechanism by
which AZM polarizes macrophages to the M2 phenotype, our investigations has
greatly narrowed the number of targets that exist. The continuation of this
research will further define these molecular targets. These investigations may
allow the development of future therapeutic agents combining the beneficial
immunomodulatory effects of AZM without the need for long term antibiotic
usage.
Modulation of macrophage polarization may provide a new avenue for
treatment of various infections. In many infections, it is the strong inflammatory
response to infectious pathogens, rather than the pathogen itself, which is
responsible for much of the damage and pathology that follows. AZM and other
future AZM-like immunomodulatory drugs may be able to blunt the immune
response, while still allowing for adequate clearance of the bacteria.
This work additionally provides the foundation for mechanistic
investigations into specific molecular targets of M2 macrophages which lead to
this immunomodulation. With AZM, we have an agent that is able to shift
macrophage polarization to the M2 phenotype. AZM is able to modulate the
immune system with few systemic complications, especially compared to other
immunomodulators (e.g. corticosteroids, methotrexate, and cyclosporine), which
profoundly suppress the immune system. This polarization is clinically relevant,
however, as AZM functions as a relatively blunt instrument to affect these
changes. It is conceivable that alterations in individual M2 effector proteins may
be able to improve outcomes in a more selective manner. It is unknown which
proteins expressed in M2 macrophages play important roles in the response to
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extracellular pathogens. The determination of which specific proteins play an
important role in the blunting of the inflammatory response to extracellular
pathogens may allow for more specific modulation of the immune system. Novel
therapeutics that allow for a shift in the balance of macrophage polarization may
allow for improved outcomes in the context of infection.
C. Conclusions
This research provides additional insights into the role of M1 and M2
macrophages during acute infections and in CF. Our research has shown that
shifting macrophage polarization away from the M1 phenotype and towards the
M2 phenotype increases survival in mice during acute infections. This shift still
allows for sufficient inflammation to clear the infection. We believe that it is the
inflammatory response that causes much of the mortality, which is especially
applicable in chronic inflammatory conditions like CF and COPD.
We conclude that shifts in macrophage phenotype towards an M2
polarization result in improved outcomes in P. aeruginosa pneumonia, and may
be responsible for improvements associated with AZM treatment in patients with
CF. We have previously shown that AZM shifts macrophage polarization away
from the M2 phenotype in the presence of cytokines that would otherwise result
in M1 polarization, and here we have expanded our knowledge of the functional
role that AZM-exposed macrophages exhibit.
We additionally investigated potential molecular targets by which AZM
polarizes macrophages to the M2 phenotype. We believe that AZM increases
IKKβ activation, and, in a manner similar to what Fong et. al. described,
preventing activation of STAT1 [68]. Further research is necessary to confirm
the exact mechanism by which AZM effects these changes. Future research
may lead to novel therapeutics that target specific aspects of alternative
macrophage activation, as an immunomodulatory modality that is clinically
effective in patients with chronic inflammatory lung diseases, while at the same
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time are less toxic and immunosuppressive than therapies that are currently
available.
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Figure 5.1. Proposed model for beneficial effects of AZM in patients with CF.
Disease progression in CF is characterized by a cycle consisting of bacterial
flares and a strong inflammatory response to the bacteria. This strong
response leads to tissue damage, and eventually tissue repair. When
excessive damage has occurred due to the immune response, scarring and
fibrosis occurs, leading to future bacterial flares. We propose that AZM
decreases the degree of the initial inflammatory response, resulting in less
extensive damage.
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